



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C12N 15/00		A2	(11) International Publication Number: <b>WO 98/12311</b>  (43) International Publication Date: 26 March 1998 (26.03.98)
<p>(21) International Application Number: PCT/US97/16042</p> <p>(22) International Filing Date: 11 September 1997 (11.09.97)</p> <p>(30) Priority Data: 60/026,294 11 September 1996 (11.09.96) US</p> <p>(71) Applicant (for all designated States except US): THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): BOYCE, Frederick, M. [US/US]; 103 Beech Street #3, Belmont, MA 02178 (US).</p> <p>(74) Agents: ELLISON, Eldora, L. et al.; Fish &amp; Richardson P.C., 601 Thirteenth Street, N.W., Washington, DC 20005 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: USE OF A NON-MAMMALIAN DNA VIRUS TO EXPRESS AN EXOGENOUS GENE IN A MAMMALIAN CELL</p> <p style="text-align: center;"><b>AcMNPV Transfer Plasmid Z4</b></p>			
<p>(57) Abstract</p> <p>Disclosed are methods, nucleic acids, and cells for expressing an exogenous gene in a mammalian cell, involving introducing into the cell a non-mammalian DNA virus (e.g., a baculovirus) whose genome carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Also disclosed are methods for treating gene deficiency disorders, neurological disorders, or cancers in a mammal by providing to a cell a therapeutically effective amount of a virus whose genome carries an exogenous, therapeutic gene and growing the cell under conditions such that the exogenous gene is expressed in the mammal.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF A NON-MAMMALIAN DNA VIRUS TO EXPRESS AN  
EXOGENOUS GENE IN A MAMMALIAN CELL

Cross-Reference to Related Application

This application claims priority under 35 U.S.C. § 119 from U.S. Serial  
5 No. 60/026,294, filed September 11, 1996.

Background of the Invention

This invention relates to the use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell.

Current methods for expressing an exogenous gene in a mammalian cell  
10 include the use of mammalian viral vectors, such as those that are derived from retroviruses, adenoviruses, herpes viruses, vaccinia viruses, polio viruses, or adeno-associated viruses. Other methods of expressing an exogenous gene in a mammalian cell include direct injection of DNA, the use of ligand-DNA conjugates, the use of adenovirus-ligand-DNA conjugates, calcium phosphate  
15 precipitation, and methods that utilize a liposome- or polycation-DNA complex. In some cases, the liposome- or polycation-DNA complex is able to target the exogenous gene to a specific type of tissue, such as liver tissue.

Typically, viruses that are used to express desired genes are constructed by removing unwanted characteristics from a virus that is known to infect, and  
20 replicate in, a mammalian cell. For example, the genes encoding viral structural proteins and proteins involved in viral replication often are removed to create a defective virus, and a therapeutic gene is then added. This principle has been used to create gene therapy vectors from many types of animal viruses such as retroviruses, adenoviruses, and herpes viruses. This method has  
25 also been applied to Sindbis virus, an RNA virus that normally infects mosquitoes but which can replicate in humans, causing a rash and an arthritis syndrome.

Non-mammalian viruses have been used to express exogenous genes in non-mammalian cells. For example, viruses of the family Baculoviridae  
30 (commonly referred to as baculoviruses) have been used to express exogenous genes in insect cells. One of the most studied baculoviruses is *Autographa*

*californica* multiple nuclear polyhedrosis virus (AcMNPV). Although some species of baculoviruses that infect crustacea have been described (Blissard, et al., 1990, Ann. Rev. Entomology 35:127), the normal host range of the baculovirus AcMNPV is limited to the order lepidoptera. Baculoviruses have 5 been reported to enter mammalian cells (Volkman and Goldsmith, 1983, Appl. and Environ. Microbiol. 45:1085-1093; Carbonell and Miller, 1987, Appl. and Environ. Microbiol. 53:1412-1417; Brusca et al., 1986, Intervirology 26:207-222; and Tjia et al., 1983, Virology 125:107-117). Although an early report of baculovirus-mediated gene expression in mammalian cells appeared, the authors 10 later attributed the apparent reporter gene activity to the reporter gene product being carried into the cell after a prolonged incubation of the cell with the virus (Carbonell et al., 1985, J. Virol. 56:153-160; and Carbonell and Miller, 1987, Appl. and Environ. Microbiol. 53:1412-1417). These authors reported that, when the exogenous gene gains access to the cell as part of the baculovirus 15 genome, the exogenous gene is not expressed *de novo*. Subsequent studies have demonstrated baculovirus-mediated gene expression in mammalian cells (Boyce and Bucher, 1996, Proc. Natl. Acad. Sci. 93:2348-2352). In addition to the Baculoviridae, other families of viruses naturally multiply only in invertebrates; some of these viruses are listed in Table 1.

20 Gene therapy methods are currently being investigated for their usefulness in treating a variety of disorders. Most gene therapy methods involve supplying an exogenous gene to overcome a deficiency in the expression of a gene in the patient. Other gene therapy methods are designed to counteract the effects of a disease. Still other gene therapy methods involve 25 supplying an antisense nucleic acid (e.g., RNA) to inhibit expression of a gene of the host cell (e.g., an oncogene) or expression of a gene from a pathogen (e.g., a virus).

30 Certain gene therapy methods are being examined for their ability to correct inborn errors of the urea cycle, for example (see, e.g., Wilson et al., 1992, J. Biol. Chem. 267: 11483-11489). The urea cycle is the predominant metabolic pathway by which nitrogen wastes are eliminated from the body. The steps of the urea cycle are primarily limited to the liver, with the first two

steps occurring within hepatic mitochondria. In the first step, carbamoyl phosphate is synthesized in a reaction that is catalyzed by carbamoyl phosphate synthetase I (CPS-I). In the second step, citrulline is formed in a reaction catalyzed by ornithine transcarbamylase (OTC). Citrulline then is transported 5 to the cytoplasm and condensed with aspartate into arginosuccinate by arginosuccinate synthetase (AS). In the next step, arginosuccinate lyase (ASL) cleaves arginosuccinate to produce arginine and fumarate. In the last step of the cycle, arginase converts arginine into ornithine and urea.

10 A deficiency in any of the five enzymes involved in the urea cycle has significant pathological effects, such as lethargy, poor feeding, mental retardation, coma, or death within the neonatal period (see, e.g., Emery et al., 1990, *In: Principles and Practice of Medical Genetics*, Churchill Livingstone, New York). OTC deficiency usually manifests as a lethal hyperammonemic coma within the neonatal period. A deficiency in AS results in citrullinemia 15 which is characterized by high levels of citrulline in the blood. The absence of ASL results in arginosuccinic aciduria (ASA), which results in a variety of conditions including severe neonatal hyperammonemia and mild mental retardation. An absence of arginase results in hyperarginemia which can manifest as progressive spasticity and mental retardation during early childhood. 20 Other currently used therapies for hepatic disorders include dietary restrictions; liver transplantation; and administration of arginine freebase, sodium benzoate, and/or sodium phenylacetate.

#### Summary of the Invention

25 It has been discovered that a non-mammalian DNA virus carrying an exogenous gene expression construct can be used to express an exogenous gene in a mammalian cell.

Accordingly, in one aspect, the invention features a method of expressing 30 an exogenous gene in a mammalian cell(s), involving introducing into the cell a non-mammalian DNA virus, the genome of which carries the exogenous gene operably linked to a mammalian-active promoter, and allowing the cell to live under conditions such that the exogenous gene is expressed.

In another aspect, the invention features a method of treating a gene deficiency disorder in a mammal (e.g., a human or a mouse), involving introducing into a cell a therapeutically effective amount of a non-mammalian DNA virus, the genome of which carries an exogenous gene, and maintaining 5 the cell under conditions such that the exogenous gene is expressed in the mammal.

Included within the invention are nucleic acids and cells for practicing the methods described herein. In particular, the invention includes a nucleic acid that includes a genome of a non-mammalian DNA virus (e.g., an insect 10 virus) and an exogenous mammalian gene that is operably linked to a "mammalian-active" promoter. Such a nucleic acid can be engineered to carry any of the various promoters and exogenous genes described herein.

Particularly useful nucleic acids are those that express a therapeutic gene. Other useful genes include, but are not limited to, RNA decoy genes, ribozyme 15 genes, and antisense genes (i.e., genes that are transcribed into RNA decoys, ribozymes, or antisense nucleic acids). If desired, the nucleic acids of the invention can be formulated into a pharmaceutical composition by admixture with a pharmaceutically acceptable excipient. Also included within the invention is a cell (e.g., a cultured, human cell) that contains any of the nucleic 20 acids of the invention.

The invention further features a method for treating a tumor in a mammal, involving introducing into a cancerous cell of the mammal (e.g., a cancerous hepatocyte) a non-mammalian DNA virus (e.g., a baculovirus) whose genome expresses a cancer-therapeutic gene (encoding, e.g., a tumor necrosis 25 factor, thymidine kinase, diphtheria toxin chimera, or cytosine deaminase). The exogenous gene can be expressed in a variety of cells, e.g., hepatocytes; neural cells such as neurons from brain, spinal cord, or peripheral nerve; adrenal medullary cells; glial cells; skin cells; spleen cells; muscle cells; kidney cells; and bladder cells. Thus, the invention can be used to treat various cancerous or 30 non-cancerous tumors, including carcinomas (e.g., hepatocellular carcinoma), sarcomas, gliomas, and neuromas. Either *in vivo* or *in vitro* methods can be used to introduce the virus into the cell in this aspect of the invention.

Preferably, the exogenous gene is operably linked to a promoter that is active in cancerous cells, but not in other cells, of the mammal. For example, the  $\alpha$ -fetoprotein promoter is active in cells of hepatocellular carcinomas and in fetal tissue but it is otherwise not active in mature tissues. Accordingly, the use of 5 such a promoter is preferred for expressing a cancer-therapeutic gene for treating hepatocellular carcinomas.

The invention also features a method for treating a neurological disorder (e.g., Parkinson's Disease, Alzheimer's Disease, or disorders resulting from 10 injuries to the central nervous system) in a mammal. The method involves (a) introducing into a cell (e.g., a cell of the central nervous system) a therapeutically effective amount of a non-mammalian DNA virus (e.g., a baculovirus), the genome of which virus includes an exogenous gene encoding 15 a therapeutic protein, and (b) maintaining the cell under conditions such that the exogenous gene is expressed in the mammal. Particularly useful exogenous genes include those that encode therapeutic proteins such as nerve growth factor, hypoxanthine guanine phosphoribosyl transferase (HGPRT), tyrosine hydroxylase, dopa-decarboxylase, brain-derived neurotrophic factor, and basic 20 fibroblast growth factor. Both neuronal and non-neuronal cells (e.g., fibroblasts, myoblasts, and kidney cells) are useful in this aspect of the invention. Such cells can be autologous or heterologous to the treated mammal. Preferably, the cell is autologous to the mammal, as such cells obviate concerns 25 about graft rejection. Preferably, the cell is a primary cell, such as a primary neuronal cell or a primary myoblast.

In each aspect of the invention, the non-mammalian DNA virus is 25 preferably an invertebrate virus (i.e., a virus that infects, and replicates in, cells of invertebrates. For example, the DNA viruses listed in Table 1 can be used in the invention. Preferably, the invertebrate DNA virus is a baculovirus, e.g., a nuclear polyhedrosis virus, such as an *Autographa californica* multiple 30 nuclear polyhedrosis virus. If desired, the nuclear polyhedrosis virus may be engineered such that it lacks a functional polyhedrin gene. Either or both the occluded form and budded form of virus (e.g., baculovirus) can be used.

**TABLE 1. NON-MAMMALIAN DNA VIRUSES THAT CAN BE USED IN THE INVENTION.<sup>1</sup>**

**I. FAMILY: BACULOVIRUSES BACULOVIRIDAE**

5 **SUBFAMILY:**  
OCCLUDED BACULOVIRUSES EUBACULOVIRINAE

**Genus:**

Nuclear polyhedrosis virus (NPV)

**Subgenus:**

10 Multiple Nucleocapsid Viruses (MNPV)

**Preferred Species:**

Autographa californica nuclear polyhedrosis virus (AcMNPV)

**Other Members:**

15 Choristoneura fumiferana MNPV (CfMNPV)  
Mamestra brassicae MNPV (MbMNPV)  
Orgyia pseudotsugata MNPV (OpMNPV)  
and approximately 400-500 species  
isolated from seven insect orders and Crustacea.

**Subgenus:**

20 Single Nucleocapsid Viruses (SNPV)

**Preferred Species:**

Bombyx mori S Nuclear Polyhedrosis Virus (BmNPV)

**Other Members:**

25 Heliothis zea SNPV (HzSnpv)  
Trichoplusia ni SNPV (TnSnpv)  
and similar viruses isolated from seven insect  
orders and Crustacea.

**Genus:**

Granulosis virus (GV)

30 **Preferred Species:**  
Plodia interpunctella granulosis virus (PiGV)

<sup>1</sup> These viruses are listed in: "Fifth Report of the International Committee on Taxonomy of Viruses" (ICTV) by Cornelia Buchen-Osmond, 1991, Research School of Biological Sciences, Canberra, Australia. Most viruses listed here are available from the American Type Culture Collection.

### Other Members:

Trichoplusia ni granulosis virus (TnGV)  
 Pieris brassicae granulosis virus (PbGV)  
 Artogeia rapae granulosis virus (ArGV)  
 Cydia pomonella granulosis virus (CpGV)  
 and similar viruses from about 50 species in the  
 Lepidoptera

#### SUBFAMILY:

## NON-OCCLUDED BACULOVIRUSES      NUDIBACULOVIRINAЕ

10 Genus:

### Non-occluded baculoviruses (NOB)

### Preferred Species:

## **Heliothis zea NOB (HzNOB)**

#### Other Members:

---

15 **Oryctes rhinoceros virus**

Additional viruses have been observed in a fungus (*Strongwellsea magna*), a spider, the European crab (*Carcinus maenas*), and the blue crab (*Callinectes sapidus*).

**20 II. FAMILY: ICOSAHEDRAL CYTOPLASMIC DEOXYRIBOVIRUSES  
IRIDOVIRIDAE**

**Genus:**

## Small iridescent Iridovirus insect virus group

### Preferred Species:

25 Chilo iridescent virus

### Other Members:

30 Insect iridescent virus 1 Insect iridescent virus 2 Insect iridescent  
 virus 6 Insect iridescent virus 9 Insect iridescent virus 10 Insect  
 iridescent virus 16 Insect iridescent virus 17 Insect iridescent virus  
 18 Insect iridescent virus 19 Insect iridescent virus 20 Insect  
 iridescent virus 21 Insect iridescent virus 22 Insect iridescent virus  
 23 Insect iridescent virus 24 Insect iridescent virus 25 Insect  
 iridescent virus 26  
 Insect iridescent virus 27 Insect iridescent virus 28 Insect iridescent  
 35 virus 29 Insect iridescent virus 30 Insect iridescent virus 31 Insect  
 iridescent virus 32

**Genus:**

Large iridescent Chloriridovirus insect virus group

**Preferred Species:**

5 Mosquito iridescent virus (iridescent virus - type  
3, regular strain)

**Other Members:**

	Insect iridescent virus 3	Insect iridescent virus 4
	Insect iridescent virus 5	Insect iridescent virus 7
	Insect iridescent virus 8	Insect iridescent virus 11
10	Insect iridescent virus 12	Insect iridescent virus 13
	Insect iridescent virus 14	Insect iridescent virus 15

**Putative member:**

Chironomus plumosus iridescent

**Genus:**

15 Frog virus group Ranavirus

**Preferred Species:**

Frog virus 3 (FV3)

**Other Members:**

20	Frog virus 1	Frog virus 2	Frog virus 5	
	Frog virus 6	Frog virus 7	Frog virus 8	
	Frog virus 9	Frog virus 10	Frog virus 11	
	Frog virus 12	Frog virus 13	Frog virus 14	
	Frog virus 15	Frog virus 16	Frog virus 17	
25	Frog virus 18	Frog virus 19	Frog virus 20	
	Frog virus 21	Frog virus 22	Frog virus 23	
	Frog virus 24	L2	L4	L5
	LT 1	LT 2	LT 3	LT 4
	T 21	T 6	T 7	T 8
30	T 9	T 10	T 11	T 12
	T 13	T 14	T 15	T 16
	T 17	T 18	T 19	T 20
	Tadpole edema virus from newts			
	Tadpole edema virus from Rana catesbeiana			
35	Tadpole edema virus from Xenopus			

**Genus:**

Lymphocystis disease virus group Lymphocystisvirus

**Preferred Species:**

Flounder isolate (LCDV-1)



## IV. FAMILY: POXVIRUS GROUP POXVIRIDAE

## SUBFAMILY:

POXVIRUSES OF VERTEBRATES

CHORDOPOXVIRINAE

## Genus:

5 Molluscum contagiosum subgroup Molluscipoxvirus

Preferred Species:

Molluscum contagiosum virus

## SUBFAMILY:

POXVIRUS OF INSECTS

ENTOMOPOXVIRINAE

## 10 Putative Genus:

Entomopoxvirus A Poxvirus of Coleoptera

Preferred Species:

Poxvirus of Melolontha

Other Members:

## 15 Coleoptera:

Anomala cuprea

Aphodius tasmaniae

Demodema boranensis

Dermolepida albohirtum

## 20 Figulus sublaevis

Geotrupes sylvaticus

## Putative Genus:

Entomopoxvirus B Poxvirus of Lepidoptera and Orthoptera

## 25 Preferred Species:

Poxvirus of Amsacta moorei (Lepidoptera)

Other Members:

## Lepidoptera:

Acrobasis zelleri

Choristoneura biennis

Choristoneura conflictana

Choristoneura diversum

Chorizagrotis auxiliaris

Operophtera brumata

## 30 Orthoptera:

Arphia conspersa

Locusta migratoria

*Melanoplus sanguinipes*  
*Oedaleus senegalensis*  
*Schistocerca gregaria*

**Putative Genus:**

5      Entomopoxvirus C      Poxvirus of Diptera

**Preferred Species:**

Poxvirus of *Chironomus luridus* (Diptera)

**Other Members:**

Diptera:

10      *Aedes aegypti*  
*Camptochironomus tentans*  
*Chironomus attenuatus*  
*Chironomus plumosus*  
*Goeldichironomus holoprasimus*

15      Other members of family Poxviridae

Albatrosspox (Avipoxvirus)

Cotia

Embu

Marmosetpox

20      Marsupialpox (Australian 'quokkas')  
Mule deer poxvirus (*Odocoileus hemionus*;  
*Capripoxvirus*)  
Volepox (*Microtus oeconomus*, *Microtus*  
*pennsylvanicus*)

25      Skunk poxvirus (*Mephitis*; *Orthopoxvirus*)

**V. GROUP CAULIFLOWER CAULIMOVIRUS MOSAIC VIRUS**

**Preferred Member:**

Cauliflower mosaic virus (CaMV) (cabbage b, davis  
isolate)

30      **Other Members:**

Blueberry red ringspot (327)   Carnation etched ring (182)      Dahlia  
mosaic (51)      Figwort mosaic      Horseradish latent  
Mirabilis mosaic      Peanut chlorotic streak      Soybean chlorotic  
mottle (331)   Strawberry vein banding (219)   Thistle mottle

35      **Putative Members:**

Aquilegia necrotic mosaic   Cassava vein mosaic  
Cestrum virus      Petunia vein clearing  
Plantago virus 4      Sonchus mottle

**VI. GROUP GEMINIVIRUS****Subgroup I (i.e., Genus)**

Maize streak virus

Preferred Member:

5 Maize streak virus (MSV) (133)

Other Members:

Chloris striate mosaic (221)

Digitaria streak

Miscanthus streak

10 Wheat dwarf

Putative Members:

Bajra streak

Bromus striate mosaic

Digitaria striate mosaic

15 Oat chlorotic stripe  
Paspalum striate mosaic**Subgroup II (i.e., Genus):**

Beet curly top virus

Preferred Member:

20 Beet curly top virus (BCTV)(210)

Other Members:

Tomato pseudo-curly top virus

Bean summer death virus

Tobacco yellow dwarf virus

25 Tomato leafroll virus

**Subgroup III (i.e., Genus):**

Bean golden mosaic virus

Preferred Member:

30 Bean golden mosaic virus (BGMV) (192)

30 Other Members:

Abutilon mosaic virus  
leaf crumple virus  
yellow mosaic virus  
mosaic virus

35 Malvaceous chlorosis virus  
Mungbean yellow mosaic virus  
Rhynchosia mosaic virus

African cassava mosaic virusCotton  
Euphorbia mosaic virusHorsegram  
Indian cassava mosaic virusJatropha  
Limabean golden mosaic virus  
Melon leaf curl virus  
Potato yellow mosaic virus  
Squash leaf curl virus

	Tigre disease virus	Tobacco leaf curl virus
	Tomato golden mosaic virus	Tomato leaf curl virus
	Tomato yellow dwarf virus	Tomato yellow leaf curl virus
	Tomato yellow mosaic virus	Watermelon curly mottle virus
5	Watermelon chlorotic stunt virus	
	Honeysuckle yellow vein mosaic virus	

	<u>Putative Members:</u>	
	Cotton leaf curl virus	Cowpea golden mosaic virus
	Eggplant yellow mosaic virus	Eupatorium yellow vein virus
10	Lupin leaf curl virus	Soyabean crinkle leaf virus
	Solanum apical leaf curl virus Wissadula mosaic virus	

**VII. FAMILY: DSDNA ALGAL VIRUSES PHYCODNAVIRIDAE**

**Genus:**

dsdna Phycovirus Phycodnavirus group

15	<u>Preferred Species:</u>	Paramecium bursaria chlorella virus - 1 (PBCV - 1)
	Viruses of:	
	Paramecium bursaria Chlorella NC64A viruses (NC64A	
	viruses)	
20	Paramecium bursaria Chlorella Pbi viruses (Pbi	viruses)
	Hydra virdis Chlorella viruses (HVCV)	

Other Members:

25	Chlorella NC64A viruses (thirty-seven NC64A viruses, including PBCV-1)		
	Chlorella virus NE-8D (CV-NE8D; synonym NE-8D)		
	CV-NYb1	CV-CA4B	CV-AL1A
	CV-NY2C	CV-NC1D	CV-NC1C
	CV-CA1A	CV-CA2A	CV-IL2A
	CV-IL2B	CV-IL3A	CV-IL3D
30	CV-SC1A	CV-SC1B	CV-NC1A
	CV-NE8A	CV-AL2C	CV-MA1E
	CV-NY2F	CV-CA1D	CV-NC1B
	CV-NYs1	CV-IL5-2s1	CV-AL2A
	CV-MA1D	CV-NY2B	CV-CA4A
35	CV-NY2A	CV-XZ3A	CV-SH6A
	CV-BJ2C	CV-XZ6E	CV-XZ4C
	CV-XZ5C	CV-XZ4A	

Chlorella Pbi viruses

40	CVA-1	CVB-1	CVG-1
	CVM-1	CVR-1	

## Hydra viridis Chlorella viruses

HVCV-1  
HVCV-2  
HVCV-3

5      **VIII. FAMILY: POLYDNAVIRUS GROUP      POLYDNAVIRIDAE**

**Genus:**  
Ichnovirus

**Preferred Species:**  
Campoletis sonorensis virus (CsV)

10      **Other Member:**  
Viruses of Glypta sp.

**Genus:**  
Bracovirus

15      **Preferred Species:**  
Cotesia melanoscela virus (CmV)

---

The genome of the non-mammalian DNA virus can be engineered to include one or more genetic elements, such as a promoter of a long-terminal repeat of a transposable element or a retrovirus (e.g., Rous Sarcoma Virus); an inverted terminal repeat of an adeno-associated virus and an adeno-associated rep gene; and/or a cell-immortalizing sequence, such as the SV40 T antigen or c-myc. If desired, the genome of the non-mammalian DNA virus can include an origin of replication that functions in a mammalian cell (e.g., an Epstein Barr Virus (EBV) origin of replication or a mammalian origin of replication). Examples of mammalian origins of replication include sequences near the dihydrofolate reductase gene (Burhans et al., 1990, Cell 62:955-965), the  $\beta$ -globin gene (Kitsberg et al., 1993, Cell 366:588-590), the adenosine deaminase gene (Carroll et al., 1993, Mol. Cell. Biol. 13:2927-2981), and other human sequences (see Krysan et al., 1989, Mol. Cell. Biol. 9:1026-1033). If desired, the origin of replication can be used in conjunction with a factor that promotes replication of autonomous elements, such as the EBNA1

gene from EBV. The genome of the non-mammalian DNA virus can include a polyadenylation signal and a mammalian RNA splicing signal (i.e., one that functions in mammalian cells) positioned for proper processing of the product of the exogenous gene. In addition, the virus may be engineered to encode a signal sequence for proper targeting of the gene product.

Where cell-type specific expression of the exogenous gene is desired, the genome of the virus can include a cell-type-specific promoter, such as a promoter that is specific for liver cells, brain cells (e.g., neuronal cells), glial cells, Schwann cells, lung cells, kidney cells, spleen cells, muscle cells, or skin cells. For example, a liver cell-specific promoter can include a promoter of a gene encoding albumin,  $\alpha$ -1-antitrypsin, pyruvate kinase, phosphoenol pyruvate carboxykinase, transferrin, transthyretin,  $\alpha$ -fetoprotein,  $\alpha$ -fibrinogen, or  $\beta$ -fibrinogen. Alternatively, a hepatitis A, B, or C viral promoter can be used. If desired, a hepatitis B viral enhancer may be used in conjunction with a hepatitis B viral promoter. Preferably, an albumin promoter is used. An  $\alpha$ -fetoprotein promoter is particularly useful for driving expression of an exogenous gene when the invention is used to express a gene for treating a hepatocellular carcinoma. Other preferred liver-specific promoters include promoters of the genes encoding the low density lipoprotein receptor,  $\alpha$ 2-macroglobulin,  $\alpha$ 1-antichymotrypsin,  $\alpha$ 2-HS glycoprotein, haptoglobin, ceruloplasmin, plasminogen, complement proteins (C1q, C1r, C2, C3, C4, C5, C6, C8, C9, complement Factor I and Factor H), C3 complement activator,  $\beta$ -lipoprotein, and  $\alpha$ 1-acid glycoprotein. For expression of an exogenous gene specifically in neuronal cells, a neuron-specific enolase promoter can be used (see Forss-Petter et al., 1990, *Neuron* 5: 187-197). For expression of an exogenous gene in dopaminergic neurons, a tyrosine hydroxylase promoter can be used. For expression in pituitary cells, a pituitary-specific promoter such as POMC may be useful (Hammer et al., 1990, *Mol. Endocrinol.* 4:1689-97).

Promoters that are inducible by external stimuli also can be used. Such promoters provide a convenient means for controlling expression of the exogenous gene in a cell of a cell culture or mammal. Preferred inducible promoters include enkephalin promoters (e.g., the human enkephalin promoter),

metallothionein promoters, and mouse mammary tumor virus promoters.

Methods for inducing gene expression from each of these promoters are known in the art.

Essentially any mammalian cell can be used in the methods of the invention; preferably, the mammalian cell is a human cell. The cell can be a primary cell (e.g., a primary hepatocyte, primary neuronal cell, or primary myoblast) or it may be a cell of an established cell line. It is not necessary that the cell be capable of undergoing cell division; a terminally differentiated cell can be used. If desired, the virus can be introduced into a primary cell approximately 22-26 hours (e.g., approximately 24 hours) after the initial plating of the primary cell to optimize the efficiency of infection. Preferably, the mammalian cell is a liver-derived cell, such as a HepG2 cell, a Hep3B cell, a Huh-7 cell, an FTO2B cell, a Hepa1-6 cell, or an SK-Hep-1 cell) or a Kupffer cell; a kidney cell, such as a cell of the kidney cell line 293, a PC12 cell (e.g., a differentiated PC12 cell induced by nerve growth factor), a COS cell (e.g., a COS7 cell), or a Vero cell; a neuronal cell, such as a fetal neuronal cell, cortical pyramidal cell, mitral cell, a granule cell, or a brain cell (e.g., a cell of the cerebral cortex; an astrocyte; a glial cell; a Schwann cell); a muscle cell, such as a myoblast or myotube (e.g., a C<sub>2</sub>C<sub>12</sub> cell); a spleen cell (e.g., a macrophage or lymphocyte); an epithelial cell, such as a HeLa cell; a fibroblast, such as an NIH3T3 cell; an endothelial cell; or a bone marrow stem cell. Other preferred mammalian cells include CHO/dhfr<sup>-</sup> cells, Ramos, Jurkat, HL60, and K-562 cells.

The virus can be introduced into a cell *in vitro* or *in vivo*. Where the virus is introduced into a cell *in vitro*, the infected cell can subsequently be introduced into a mammal, if desired. Accordingly, expression of the exogenous gene can be accomplished by maintaining the cell *in vitro*, *in vivo*, or *in vitro* and *in vivo*, sequentially. Similarly, where the invention is used to express an exogenous gene in more than one cell, a combination of *in vitro* and *in vivo* methods may be used to introduce the gene into more than one mammalian cell.

If desired, the virus can be introduced into the cell by administering the virus to a mammal that carries the cell. For example, the virus can be administered to a mammal by subcutaneous, intravascular, or intraperitoneal injection. If desired, a slow-release device, such as an implantable pump, may 5 be used to facilitate delivery of the virus to cells of the mammal. A particular cell type within a mammal can be targeted by modulating the amount of the virus administered to the mammal and by controlling the method of delivery. For example, intravascular administration of the virus to the portal, splenic, or 10 mesenteric veins or to the hepatic artery may be used to facilitate targeting the virus to liver cells. In another method, the virus may be administered to cells or organ of a donor individual (human or non-human) prior to transplantation 15 of the cells or organ to a recipient.

In a preferred method of administration, the virus is administered to a tissue or organ containing the targeted cells of the mammal. Such 15 administration can be accomplished by injecting a solution containing the virus into a tissue, such as skin, brain (e.g., the olfactory bulb), kidney, bladder, trachea, liver, spleen, muscle, thyroid, thymus, lung, or colon tissue. Alternatively, or in addition, administration can be accomplished by perfusing 20 an organ with a solution containing the virus, according to conventional perfusion protocols.

In another preferred method, the virus is administered intranasally, e.g., by applying a solution of the virus to the nasal mucosa of a mammal. This method of administration can be used to facilitate retrograde transportation of the virus into the brain. This method thus provides a means for delivering the 25 virus to brain cells, (e.g., mitral and granule neuronal cells of the olfactory bulb) without subjecting the mammal to surgery.

In an alternative method for using the virus to express an exogenous gene in the brain, the virus is delivered to the brain by osmotic shock according to conventional methods for inducing osmotic shock.

30 Where the cell is maintained under *in vitro* conditions, conventional tissue culture conditions and methods may be used. In a preferred method, the cell is maintained on a substrate that contains collagen, such as Type I collagen

or rat tail collagen, or a matrix containing laminin. As an alternative to, or in addition to, maintaining the cell under *in vitro* conditions, the cell can be allowed to live under *in vivo* conditions (e.g., in a human). Implantable versions of collagen substrates are also suitable for maintaining the virus-infected cells under *in vivo* conditions in practicing the invention (see, e.g., Hubbell et al., 1995, Bio/Technology 13:565-576 and Langer and Vacanti, 1993, Science 260: 920-925).

The invention can be used to express a variety of exogenous genes encoding gene products such as a polypeptides or proteins, antisense RNAs, and catalytic RNAs. If desired, the gene product (e.g., protein or RNA) can be purified from the mammalian cell. Thus, the invention can be used in the manufacture of a wide variety of proteins that are useful in the fields of biology and medicine.

An "antisense" nucleic acid is a nucleic acid molecule (i.e., DNA or RNA) that is complementary (i.e., able to hybridize *in vivo* or under stringent *in vitro* conditions) to all or a portion of a nucleic acid (e.g., a gene or mRNA) that encodes a polypeptide of interest. If desired, conventional methods can be used to produce an antisense nucleic acid that contains desirable modifications. For example, a phosphorothioate oligonucleotide can be used as the antisense nucleic acid in order to inhibit degradation of the antisense oligonucleotide by nucleases *in vivo*. Where the antisense nucleic acid is complementary to a portion of the nucleic acid encoding the polypeptide of interest, the antisense nucleic acid should hybridize close enough to the 5' end of the nucleic acid such that it inhibits translation of a functional polypeptide (i.e., a polypeptide that carries out an activity that one wishes to inhibit (e.g., an enzymatic activity)). Typically, this means that the antisense nucleic acid should be complementary to a sequence that is within the 5' half or third of the gene to which it hybridizes. As used herein, an "antisense gene" is a nucleic acid that encodes an antisense nucleic acid. Typically, such an antisense gene includes all or a portion of the gene the expression of which is to be inhibited, but the antisense gene is operably linked to a promoter such that the antisense

gene is in the opposite orientation, relative to the orientation of the gene that is to be inhibited.

Where the invention is used to express an antisense RNA, the preferred antisense RNA is complementary to a nucleic acid (e.g., an mRNA) of a pathogen of the mammalian cell (e.g., a virus, a bacterium, or a fungus). For example, the invention can be used in a method of treating a hepatitis viral infection by expressing an antisense RNA that hybridizes to an mRNA of an essential hepatitis virus gene product (e.g., a polymerase mRNA). Other preferred antisense RNAs include those that are complementary to a naturally-occurring gene in the cell, which gene is expressed at an undesirably high level. For example, an antisense RNA can be designed to inhibit expression of an oncogene in a mammalian cell. Similarly, the virus can be used to express a catalytic RNA (i.e., a ribozyme) that inhibits expression of a target gene in the cell by hydrolyzing an mRNA encoding the targeted gene product. Antisense RNAs and catalytic RNAs can be designed by employing conventional criteria.

If desired, the invention can be used to express a dominant negative mutant in a mammalian cell. For example, viral assembly in a cell can be inhibited or prevented by expressing in that cell a dominant negative mutant of a viral capsid protein (see, e.g., Scaglioni et al., 1994, *Virology* 205:112-120; Scaglioni et al., 1996, *Hepatology* 24:1010-1017; and Scaglioni et al., 1997, *J. Virol.* 71:345-353).

The invention can be used to express any of various "therapeutic" genes in a cell. A "therapeutic" gene is one that, when expressed, confers a beneficial effect on the cell or tissue in which it is present, or on a mammal in which the gene is expressed. Examples of "beneficial effects" include amelioration of a sign or symptom of a condition or disease, prevention or inhibition of a condition or disease, or conferral of a desirable characteristic, including even temporary amelioration of signs or symptoms of a disorder. Included among the therapeutic genes are those genes that correct a gene deficiency disorder in a cell or mammal ("correction of a disorder need not be equivalent to curing a patient suffering from a disorder). For example, carbamoyl synthetase I can correct a gene deficiency disorder when it is expressed in a cell that previously

failed to express, or expressed insufficient levels of, carbamoyl synthetase I. Also included are genes that are expressed in one cell, yet which confer a beneficial effect on a second cell. For example, a gene encoding insulin can be expressed in a pancreatic cell from which the insulin is then secreted to exert a 5 beneficial effect on other cells of the mammal. Other therapeutic genes include sequences that are transcribed into antisense RNAs that inhibit transcription or translation of a gene that is expressed at an undesirably high levels. Also included are antisense genes that encode a nucleic acid that inhibits expression of a gene that is expressed at an undesirable level. For example, an antisense 10 gene that inhibits expression of a gene encoding an oncogenic protein is considered a therapeutic gene. "Cancer therapeutic" genes are those genes that confer a beneficial effect on a cancerous cell or a mammal suffering from cancer. Particularly useful cancer therapeutic genes include the p53 gene, a herpes simplex virus thymidine kinase gene, and an antisense gene that is 15 complementary to an oncogene.

The invention can be used to express a therapeutic gene in order to treat a disorder (e.g., a gene deficiency disorder). Particularly appropriate genes for expression include those genes that thought to be expressed at a less than normal level in the target cells of the subject mammal. Particularly useful 20 gene products include carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, and arginase. Other desirable gene products include fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, low-density-lipoprotein receptor, porphobilinogen deaminase, factor VIII, factor IX, cystathione  $\beta$ -synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin,  $\beta$ -glucosidase, pyruvate carboxylase, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase (also referred to as P-protein), H-protein, T-protein, Menkes disease copper- 25 transporting ATPase, and Wilson's disease copper-transporting ATPase. Other examples of desirable genes for expression with the invention include genes 30

encoding tumor suppressors (e.g., p53), insulin, or CFTR (e.g., for treating cystic fibrosis).

The invention can also be used to express in a mammalian cell a gene that is expected to have a biological effect in mammals but not in insects (i.e., 5 a "mammal-specific" gene). For example, a baculovirus genome can be used to express a mammalian myoD gene and thereby produce muscle proteins; such a gene would be expected to have a biological effect in mammalian cells but not insect cells. Other examples of mammal-specific genes include, but are not limited to, transcription factors that function in mammalian, but not insect, 10 cells. For example, the transcription factors c/ebp-alpha and chop10 will activate liver cell differentiation pathways when expressed from an insect genome (e.g., a baculovirus genome) in a mammalian cell. In contrast, expression of these mammal-specific transcription factors in an insect cell would be expected to have a minimal, or no, effect on the insect cell.

15 If desired, the vectors of the invention can be used to propagate genetic constructs in non-mammalian (e.g., insect) cells, with the advantage of inhibiting DNA methylation of the product. It has been observed that a promoter may become methylated in cell lines or tissues in which it is not normally expressed, and that such methylation is inhibitory to proper tissue 20 specific expression (Okuse et al., 1997, Brain Res. Mol. Brain Res. 46:197-207; Kudo et al., 1995, J. Biol. Chem. 270:13298-13302). For example, a neural promoter may become methylated in a non-neural mammalian cell. By using, for example, insect cells (e.g., Sf9 cells) to propagate a baculovirus carrying an 25 exogenous gene and a mammalian promoter (e.g., a neural promoter), the invention provides a means for inhibiting DNA methylation of the promoter prior to administration of the baculovirus and exogenous gene to the mammalian cell in which the exogenous gene will be expressed (e.g., a neural cell).

#### Definitions

30 By "non-mammalian" DNA virus is meant a virus that has a DNA genome (rather than RNA) and which is naturally incapable of replicating in a vertebrate, and specifically a mammalian, cell. Included are insect viruses (e.g.,

baculoviruses), amphibian viruses, plant viruses, and fungal viruses. Viruses that naturally replicate in prokaryotes are excluded. Examples of viruses that are useful in practicing the invention are listed in Table 1. As used herein, a "genome" can include all or some of the nucleic acid sequences present in a naturally-occurring non-mammalian DNA virus. If desired, genes or sequences can be removed from the virus genome or disabled (e.g., by mutagenesis), provided that the retains, or is engineered to retain, its ability to express an exogenous gene in a mammalian cell. For example, the virus can be engineered such that it lacks a functional polyhedrin gene. Such a virus can be produced by deleting all or a portion of the polyhedrin gene from a virus genome (e.g., a baculovirus genome) or by introducing mutations (e.g., a frameshift mutation) into the polyhedrin gene so that the activity of the gene product is inhibited.

By "insect" DNA virus is meant a virus that has a DNA genome and which is naturally capable of replicating in an insect cell (e.g., Baculoviridae, Iridoviridae, Poxviridae, Polydnnaviridae, Densoviridae, Caulimoviridae, and Phycodnaviridae).

By "positioned for expression" is meant that the DNA sequence that includes the reference gene (e.g., the exogenous gene) is positioned adjacent to a DNA sequence that directs transcription of the DNA and, if desired, translation of the RNA (i.e., facilitates the production of the desired gene product).

By "promoter" is meant at least a minimal sequence sufficient to direct transcription. A "mammalian-active" promoter is one that is capable of directing transcription in a mammalian cell. The term "mammalian-active" promoter includes promoters that are derived from the genome of a mammal, i.e., "mammalian promoters," and promoters of viruses that are naturally capable of directing transcription in mammals (e.g., an MMTV promoter or a hepatitis viral promoter). Other promoters that are useful in the invention include those promoters that are sufficient to render promoter-dependent gene expression controllable for cell-type specificity, cell-stage specificity, or tissue-specificity (e.g., liver-specific promoters), and those promoters that are

"inducible" by external signals or agents (e.g., metallothionein, MMTV, and pENK promoters); such elements can be located in the 5' or 3' regions of the native gene. The promoter sequence can be one that does not occur in nature, so long as it functions in a mammalian cell. An "inducible" promoter is a 5 promoter that, (a) in the absence of an inducer, does not direct expression, or directs low levels of expression, of a gene to which the inducible promoter is operably linked; or (b) exhibits a low level of expression in the presence of a regulating factor that, when removed, allows high-level expression from the promoter (e.g., the *tet* system). In the presence of an inducer, an inducible 10 promoter directs transcription at an increased level.

By "operably linked" is meant that a gene and a regulatory sequence(s) (e.g., a promoter) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

15 By "cell-immortalizing sequence" is meant a nucleic acid that, when present in a mammalian cell, is capable of transforming the cell for prolonged inhibition of senescence. Included are SV40 T-antigen, c-myc, telomerase, and E1A.

20 By "antisense" nucleic acid is meant a nucleic acid molecule (i.e., RNA) that is complementary (i.e., able to hybridize *in vivo* or under stringent *in vitro* conditions) to all or a portion of a target nucleic acid (e.g., a gene or mRNA) that encodes a polypeptide of interest. If desired, conventional methods can be used to produce an antisense nucleic acid that contains 25 desirable modifications. For example, a phosphorothioate oligonucleotide can be used as the antisense nucleic acid in order to inhibit degradation of the antisense oligonucleotide by nucleases *in vivo*. Where the antisense nucleic acid is complementary to only a portion of the target nucleic acid encoding the polypeptide to be inhibited, the antisense nucleic acid should hybridize close enough to some critical portion of the target nucleic acid (e.g., in the translation 30 control region of the non-coding sequence, or at the 5' end of the coding sequence) such that it inhibits translation of a functional polypeptide (i.e., a polypeptide that carries out an activity that one wishes to inhibit (e.g., an

enzymatic activity)). Typically, this means that the antisense nucleic acid should be complementary to a sequence that is within the 5' half or third of a target mRNA to which the antisense nucleic acid hybridizes. As used herein, an "antisense gene" is a nucleic acid that is transcribed into an antisense RNA.

5      Typically, such an antisense gene includes all or a portion of the target nucleic acid, but the antisense gene is operably linked to a promoter such that the orientation of the antisense gene is opposite to the orientation of the sequence in the naturally-occurring gene.

Use

10     The invention is useful for expressing an exogenous gene(s) in a mammalian cell *in vitro* or *in vivo* (e.g., a HepG2 cell). This method can be employed in the manufacture of proteins to be purified, such as proteins that are administered as pharmaceutically agents (e.g., insulin). The virus of the invention can also be used therapeutically. For example, the invention can be used to express in a patient a gene encoding a protein that corrects a deficiency in gene expression. In alternative methods of therapy, the invention can be used to express any protein, antisense RNA, or catalytic RNA in a cell.

15     The non-mammalian viral expression system of the invention offers several advantages. The invention allows for *de novo* expression of an exogenous gene; thus, detection of the exogenous protein (e.g.,  $\beta$ -galactosidase) in an infected cell represents protein that was actually synthesized in the infected cell, as opposed to protein that is carried along with the virus aberrantly. The non-mammalian viruses used in accordance with the invention are not normally pathogenic to humans; thus, concerns about safe handling of 20    these viruses are minimized. Similarly, because the majority of naturally- occurring viral promoters are not normally active in a mammalian cell, production of undesired viral proteins is minimized. While traditional gene therapy vectors are based upon defective viruses that are propagated with helper virus or on a packaging line, the invention employs a virus that is not defective for growth on insect cells for purposes of propagation, but is intrinsically, and desirably, defective for growth on mammalian cells. Accordingly, in contrast to 25    some mammalian virus-based gene therapy methods, the non-mammalian virus-

based methods of the invention should not provoke a host immune response to the viral proteins.

The non-mammalian virus used in accordance with the invention can be propagated with cells grown in serum-free media, eliminating the risk of adventitious infectious agents occasionally present in the serum contaminating a virus preparation. In addition, the use of serum-free media eliminates a significant expense faced by users of mammalian viruses. Certain non-mammalian viruses, such as baculoviruses, can be grown to a high titer (i.e., 10<sup>8</sup> pfu/ml). Generally, the large virus genomes that can be used (e.g., the baculovirus genome at 130 kbp) can accept large exogenous DNA molecules (e.g., 100 kb). In certain embodiments, the invention employs a virus whose genome has been engineered to contain an exogenous origin of replication (e.g., the EBV *oriP*). The presence of such sequences on the virus genome allows episomal replication of the virus, increasing persistence in the cell. Where the invention is used in the manufacture of proteins to be purified from the cell, the invention offers the advantage that it employs a mammalian expression system. Accordingly, one can expect proper post-translational processing and modification (e.g., glycosylation) of the gene product.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

#### Brief Description of the Drawings

Fig. 1 is a schematic representation of the AcMNPV RSV-lacZ transfer plasmid pZ4.

Fig. 2 is a schematic representation of the occluded AcMNPV RSV-lacZ transfer plasmid pZ5.

Fig. 3 is a schematic representation of the episomal transfer plasmid pZ-EBV#1, a chimera of baculovirus and Epstein Barr Virus sequences. A virus produced with this transfer plasmid is capable of replicating in a mammalian cell.

Fig. 4A is a schematic representation of a transfer plasmid that allows excision of a gene cassette. Fig. 4B is a schematic representation of the gene

cassette excised by the transfer plasmid of Fig. 4A. Excision of the gene cassette is mediated by cre-lox recombination. This strategy allows persistence of an exogenous gene in the absence of viral sequences.

Fig. 5 is a schematic representation of the transfer plasmid, pBV-  
5 AVneo, a chimera of baculovirus and Adeno-associated virus sequences. This plasmid is capable of integrating into the genome of the infected cell.

Fig. 6 is a schematic representation of the AcMNPV transfer plasmid pCMV-BV.

Fig. 7 is a schematic representation of the AcMNPV transfer plasmid  
10 pCMVZ-BV.

Fig. 8 is a schematic representation of the AcMNPV transfer plasmid pAct-BV.

Fig. 9 is a schematic representation of the AcMNPV transfer plasmid  
15 pAZ-BV.

Fig. 10 is a schematic representation of the AcMNPV transfer plasmid pIE45-BV.

Fig. 11 is a schematic representation of the AcMNPV transfer plasmid pNSE4-BV.

Fig. 12 is a schematic representation of the AcMNPV transfer plasmid  
20 pTH/SV40/BP9.

Fig. 13 is a schematic representation of the AcMNPV transfer plasmid pTH-Lac/BP9.

Figs. 14A-D are photographs of cells that were stained with X-gal one day post-infection with an AcMNPV virus containing a RSV-*lacZ* cassette.

25 Cells expressing the *lacZ* gene stain darkly with X-gal. Fig. 14A is a photograph of a typical field of HepG2 cells infected at a multiplicity of infection of 15. Fig. 14B is a photograph of a typical field of HepG2 cells infected at a multiplicity of infection of 125; over 25% of the cells were stained. Fig. 14C is a typical field of Sk-Hep-1 cells infected at a multiplicity of infection of 125, showing no positively-stained cells. Fig. 14D is a less typical field of Sk-Hep-1 cells infected at a multiplicity of infection of 125 showing a positively-stained cell. Bar = 55  $\mu$ m.

Fig. 15 is a photograph of cells obtained following baculovirus-mediated gene transfer into primary cultures of rat hepatocytes. Over 70% of the cells were stained blue.

Fig. 16 is a graph displaying the dose-dependence of baculovirus-mediated gene transfer. Here,  $10^6$  HepG2 cells were seeded into 60 mm petri dishes, and one day later the cells were exposed to the indicated dose of an AcMNPV virus containing a RSV-*lacZ* cassette (viral titer =  $1.4 \times 10^9$  pfu/ml). At one day post-infection, the cells were harvested, and extracts were prepared and assayed for  $\beta$ -galactosidase enzyme activity. Extract activity is expressed in units of  $\beta$ -galactosidase activity as previously defined (Norton and Coffin, 1985, Mol. Cell. Biol. 5:281-290). Enzyme activity was normalized for the protein content of each extract. Each point is the average of three independent assays, with the error bars representing the standard deviation.

Fig. 17 is a graphic representation of results obtained in a time course of baculovirus-mediated expression. HepG2 cells were infected with AcMNPV virus containing a RSV-*lacZ* cassette (multiplicity of infection = 5) at time zero. After one hour, the medium containing the virus was removed and replaced with fresh medium. Infected cells were harvested at the indicated time points and assayed for  $\beta$ -galactosidase activity as is described above. Each plotted point is expressed as the average of three independent assays, with the error bars representing the standard deviation. Expression from the virus peaked 12-24 hours post-infection and declined thereafter when normalized to total cellular protein.

Fig. 18 is a schematic representation of various baculoviral transfer vectors, in which an exogenous gene is operably linked to a viral or mammalian promoter.

#### Detailed Description

##### I. Genetic Manipulation of Viruses

In contrast to conventional gene expression methods, the invention involves modifying non-mammalian DNA viruses that do not naturally infect and replicate in mammalian cells. Thus, the invention is based on the addition of new properties to a non-mammalian DNA virus that allow it to deliver a

gene to a mammalian cell and allow for expression of the gene within the cell. In contrast, conventional gene therapy vectors are require that one disable viral functions, such as expression of viral genes and viral genome replication.

5 In the present method, the viral particle serves as a "shell" for the delivery of DNA to the mammalian cell. The viral DNA is engineered to contain transcriptional control sequences that are active in a mammalian cell, to allow expression of the gene of interest in the target cell. Conventional recombinant DNA techniques can be used for inserting such sequences. Because the non-mammalian DNA viruses used in accordance with the 10 invention are not capable of replicating in mammalian cells, it is not necessary to delete essential viral functions to render them defective. Preferably, the genome of the virus is normally transported to the nucleus in its natural host species because nuclear localization signals function similarly in invertebrate and in mammalian cells.

15 Preferably, the viral capsid or envelope contains a ligand that binds to mammalian cells to facilitate entry. Viruses propagated in invertebrate species (e.g., insects, plants, or fungi) do not normally terminate glycoproteins with sialic acid, and thus the viral ligand is often an asialoglycoprotein that binds to mammalian lectins (e.g., the hepatic asialoglycoprotein receptor), facilitating 20 entry into mammalian cells.

In addition, it is preferred that the virus naturally replicate in a eukaryotic species. Examples of viruses that can be engineered to express exogenous gene in accordance with the invention are listed in Table 1.

25 Established methods for manipulating recombinant viruses may be incorporated into these new methods for expressing an exogenous gene in a mammalian cell. For example, viral genes can be deleted from the virus and supplied in *trans* via packaging lines. Deletion of such genes may be desired in order to (1) suppress expression of viral gene products that may provoke an immune response, (2) provide additional space in the viral vector, or (3) 30 provide additional levels of safety in maintaining the virus in a cell.

Because most promoters of non-mammalian viruses are not active in mammalian cells, the exogenous gene should be operably linked to a promoter

that is capable of directing gene expression in a mammalian cell. Examples of suitable promoters include the RSV LTR, the SV40 early promoter, CMV IE promoters (e.g., the human CMV IE1 promoter), the adenovirus major late promoter, and the Hepatitis B viral promoter. In addition, promoters that are 5 cell-type-specific, stage-specific, or tissue-specific can be used. For example, several liver-specific promoters, such as the albumin promoter/enhancer, have been described (see, e.g., Shen et al., 1989, DNA 8:101-108; Tan et al., 1991, Dev. Biol. 146:24-37; McGrane et al., 1992, TIBS 17:40-44; Jones et al., J. Biol. Chem. 265:14684-14690; and Shimada et al., 1991, FEBS Letters 10 279:198-200). Where the invention is used to treat a hepatocellular carcinoma, an  $\alpha$ -fetoprotein promoter is particularly useful. This promoter is normally active only in fetal tissue; however, it is also active in liver tumor cells (Huber et al., 1991, Proc. Natl. Acad. Sci. 88:8039-8043). Accordingly, an  $\alpha$ -fetoprotein promoter can be used to target expression of a liver-cancer 15 therapeutic to liver tumor cells.

If desired, the virus genome can be engineered to carry an origin of replication in order to facilitate persistence of the exogenous gene in the mammalian cell. Origins of replication derived from mammalian cells (i.e., "mammalian origins of replication") have been identified (Burhans et al., 1994, Science 263:639-640). Other origins of replication, such as the Epstein-Barr Virus *oriP*, can also facilitate maintenance of expression in the presence of appropriate *trans*-acting factors, such as EBNA-1. If desired, the virus genome can be engineered to express more than one exogenous gene (e.g., the virus can be engineered to express both OTC and AS).

25 Descriptions of several viruses that can be used in the invention now follow. These examples are provided for illustrative purposes, and are not meant to limit the scope of invention.

## II. Examples of Transfer Plasmids

30 Construction of the pZ4 Transfer Plasmid: Genetic manipulation of a baculovirus for use in the invention can be accomplished with commonly-known recombination techniques originally developed for expressing proteins in

baculovirus (see, e.g., O'Reilly et al., 1992, *In: Baculovirus expression vectors*, W. H. Freeman, New York). In this example, an AcMNPV was constructed by interrupting the polyhedrin gene of the virus with a cassette that directs expression of a reporter gene. The reporter gene cassette included DNA sequences corresponding to the Rous Sarcoma Virus (RSV) promoter operably linked to the *E. coli lacZ* gene (Fig. 1). The reporter gene cassette also included sequences encoding Simian Virus 40 (SV40) RNA splicing and polyadenylation signals.

The RSV-lacZ AcMNPV transfer plasmid used in several examples set forth below is named pZ4 and was constructed as follows. An 847 bp fragment of pRSVPL9 including the SV40 RNA splicing signal and polyadenylation signal was excised using *Bgl*II and *Bam*HI. Plasmid pRSVPL9 was derived from pRSVglobin (Gorman et al., *Science* 221:551-553) by digesting pRSVglobin with *Bgl*II, adding a *Hind*III linker, and then cleaving the DNA with *Hind*III. A double-stranded polylinker made by hybridization of the oligonucleotides 5'AGCTGTCGACTCGAGGTACCAGATCTCTAGA3' (SEQ ID NO: 1) and 5'AGCTTCTAGAGATCTGGTACCTCGAGTCGAC3' (SEQ ID NO: 2) was ligated to the 4240 bp fragment having the RSV promoter and SV40 splicing and polyadenylation signals. The resulting plasmid has the polylinker in place of the globin sequences. The SV40 sequence of pRSVPL9 was cloned into the *Bam*HI site of pVL1392 (Invitrogen and Pharmingen) using standard techniques. The resulting intermediate plasmid was named pVL/SV40. An RSV-lacZ cassette was excised from pRSVlacZII (Lin et al., 1991, *Biotechniques* 11:344-348, and 350-351) with *Bgl*II and *Spe*I and inserted into the *Bgl*II and *Xba*I sites of pVL/SV40.

The AcMNPV RSV-lacZ virus, termed Z4, was prepared by homologous recombination of the Z4 transfer plasmid with linearized AcMNPV DNA. The AcMNPV virus used to prepare this DNA was AcV-EPA (Hartig et al., 1992, *J. Virol. Methods* 38:61-70).

**30 Construction of the pZ5 Transfer Plasmid:** Certain non-mammalian viruses (e.g., baculoviruses) may be occluded in a protein inclusion body, or they may exist in a plasma membrane budded form. Where an occluded virus

is used in the invention, the virus may first be liberated from the protein inclusion body, if desired. Conventional methods employing alkali may be used to release the virus (O'Reilly et al., 1992, *In: Baculovirus expression vectors*, W. H. Freeman, New York). An occluded, alkali-liberated baculovirus 5 may be taken up by a cell more readily than is the non-occluded budded virus (Volkman and Goldsmith, 1983, *Appl. and Environ. Microbiol.* 45:1085-1093). To construct the Z5 transfer plasmid (Fig. 2), for using an occluded virus in the invention, the RSV-lacZ cassette was excised from the pZ4 transfer plasmid using *Bgl*II and *Bam*HI and then inserted into the *Bgl*II site of pAcUW1 10 (Weyer et al., 1990, *J. Gen. Virol.* 71:1525-1534).

Construction of the pZ-EBV#1 Transfer Plasmid: The non-mammalian DNA viruses used in the invention may be engineered to permit episomal replication of the virus in the mammalian cell. Such a virus would persist longer, thereby optimizing methods for long-term expression of an exogenous 15 gene in a cell. An example of such a replicating virus is Z-EBV#1 (Fig. 3), which was constructed as follows. The EBV *oriP* and EBNA-1 region was excised from pREP9 (Invitrogen) using *Eco*RI and *Xba*I and then inserted into the baculoviral transfer plasmid pBacPAK9 (Clontech) at its *Eco*RI and *Xba*I sites, yielding pEBVBP9. The RSV-lacZ cassette was excised from transfer 20 plasmid pZ4 with *Bgl*II and *Bam*HI and then inserted into the *Bam*HI site of pEBVBP9 to yield the plasmid pZ-EBV#1.

Construction of pZ4loxP: The Z4loxP viral genome is a substrate for recombination with bacteriophage P1 cre recombinase. This virus can be used to insert gene cassettes bearing a loxP site into the virus using standard 25 procedures (Patel et al., 1992, *Nucl. Acids Res.* 20:97-104). A variation of this insertion system may be engineered so that the viral sequences are excised from the remaining gene expression sequences. For example, an auto-excising transfer plasmid may be constructed (Figs. 4A-4B) to express an exogenous gene in a mammalian cell. This plasmid contains loxP sequences which 30 facilitate excision of the baculoviral sequences. The pZ4loxP transfer plasmid was constructed by inserting a synthetic loxP site into the Z4 transfer plasmid. Two loxP oligonucleotides were synthesized and annealed to each other. The

oligonucleotides were:

5'GATCTGACCTAATAACTTCGTATAGCATACATTATACGAAGTTATAT

TAAGG3' (SEQ ID NO: 3) and

5'GATCCCTTAATATAACTTCGTATAATGTATGCTATACGAAGTTATTA

5 GGTCA3' (SEQ ID NO:4). The oligonucleotides were annealed by heating them to 80° C in the presence of 0.25 M NaCl and then allowing the mixture to cool slowly to room temperature before use in the ligation reactions. The annealed oligonucleotides were then ligated to the Z4 transfer plasmid that had been digested with *Bgl*II. The ligations and analysis of the resulting clones 10 were performed with standard cloning techniques. Recombinant Z4loxP baculovirus was then generated with conventional methods for recombination into linear baculoviral DNA.

Construction of pBV-AVneo, an AAV Chimera Transfer Plasmid: A baculovirus genome that is capable of integrating into a chromosome of the 15 host cell can also be used in the invention. Such an integrated virus may persist in the cell longer than a non-integrated virus. Accordingly, methods of gene expression involving such viruses may obviate the need for repeated administration of the virus to the cell, thereby decreasing the likelihood of mounting an immune response to the virus. The transfer plasmid pBV-AVneo 20 (Fig. 5) includes the inverted terminal repeats of an Adeno-associated virus (AAV). This transfer plasmid was constructed by excising the *neo* gene, which encodes G418-resistance, as a *Bgl*II-*Bam*HI fragment from pFasV.neo and inserting the fragment into the *Bam*HI site of pAVgal in place of the *lacZ* gene. Plasmid pAVgal was constructed by replacing the rep and cap coding sequences 25 of AAV with a CMV promoter and a *lacZ* gene. The resulting intermediate fragment, termed pAV.neo, was digested with *Pvu*I. The large *Pvu*I fragment, which has the CMV promoter driving expression of the *neo* gene, flanked by the AAV ITRs, then was inserted into the *Pac*I site of pBacPAK9. If desired, a 30 suitable promoter operably linked to an AAV rep gene may be inserted into this construct (e.g., between the AAV ITR and the polyhedrin promoter) to facilitate excision and recombination into the genome. Examples of rep genes that may be inserted into this construct include rep40, rep52, rep68, and rep78.

Construction of the pCMV-BV Transfer Plasmid: The human cytomegalovirus immediate early promoter, a 758 bp *Hind*III-*Xba*I fragment, was excised from pCMV-EBNA (Invitrogen) at *Hind*III, *Bam*HI and inserted into the *Hind*III sites of pBluescript (SKII<sup>+</sup>), yielding plasmid pCMV-SKII<sup>+</sup>.  
5 The promoter was then excised from CMV-SKII<sup>+</sup> at the *Xho*I, *Bam*HI sites and inserted into the *Xho*I, *Bgl*II sites of pSV/BV, yielding plasmid pCMV-BV (Fig. 6). pSV/BV is a modified version of the baculovirus transfer plasmid pBacPAK9 (Clontech), containing an altered polylinker and SV40 splice and polyadenylation signals. pSV/BV was constructed by restriction of pBacPAK9  
10 with *Not*I, treatment with T4 DNA polymerase to create blunt ends, and self-ligation to remove the *Not*I site. A new *Not*I site was then added by ligation of the linker pGCGGCCGC into the *Sma*I site. Finally, SV40 splice and polyadenylation sequences were added by digestion of pRSVPL with *Bgl*II-  
15 *Bam*HI, and insertion of the 847 bp fragment into the *Bam*HI site of the modified BacPAK9, yielding pSV/BV.

Construction of the pCMVZ-BV Transfer Plasmid: pCMVZ-BV (Fig. 7) was constructed by restriction of pCMV-BV with *Not*I and ligation insertion of a 3 kb lacZ fragment. The lacZ fragment was prepared by restriction of pAlb-Gal with *Not*I.

Construction of the pAct-BV Transfer Plasmid: The 345 bp rat  $\beta$ -actin promoter was excised from pINA (Morgenstern, JP, 1989, Ph.D. Thesis, University College, London, UK) at *Bgl*II, *Bam*HI and inserted into the *Bgl*II site of pSV/BV, yielding pAct-BV (Fig. 8).

Construction of the pAZ-BV Transfer Plasmid: pAZ-BV (Fig. 9) was constructed by restriction of pAct-BV with *Not*I and ligation insertion of a 3 kb lacZ fragment. The lacZ fragment was prepared by restriction of pAlb-Gal with *Not*I.

Construction of the pIE45-BV Transfer Plasmid: pIE45-BV (Fig. 10) was constructed by restriction of pHHSVPrPUC (Neve et al., 1997, Neuroscience 79:435-447) with *Sph*I, followed by treatment with T4 DNA polymerase in the presence of nucleotide triphosphates to create blunt ends. *Pst*I linkers (New England Biolabs, Catalog #1024, pGCTGCAGC) were then

added by treatment with T4 DNA ligase, the fragment of approximately 850 bp was subjected to digestion with *Pst*I, and cloned into the *Pst*I site of pSV/BV.

Construction of the pNSE4-BV Transfer Plasmid: pNSE4-BV (Fig. 11) was constructed by restriction of pNSE4 (see, e.g., Quon et al., 1991, *Nature* 352:239-241 and Forss-Petter et al., 1990, *Neuron* 5:187-197) with *Sal*I and *Eco*RI, followed by ligation into the *Xba*I and *Eco*RI sites of pSV/BV.

Construction of the pTH/SV40/BP9 Transfer Plasmid: pTH/SV40/BP9 (Fig. 12) was constructed by restriction of pTH4.8 Thdno (Banerjee et al., 1992, *J. Neuroscience* 12:4460-4467) with *Eco*RI and *Not*I, and ligation of the 4.0 kb promoter fragment into pSV/BV, which was also digested with *Eco*RI and *Not*I.

Construction of the pTH-Lac/BP9 Transfer Plasmid: pThlac (Fig. 13) was constructed by restriction of pALB-Gal with *Not* I and isolation of the 3 kb lacZ fragment, which was then ligated into pTH/SV40/BP9 which was also restricted with *Not* I using T4 DNA ligase.

Propagation of Viruses: Conventional methods can be used to propagate the viruses used in the invention (see, e.g., Burleson, et al., 1992, *Virology: A Laboratory Manual*, Academic Press, Inc., San Diego, CA and Mahy, ed., 1985, *Virology: A Practical Approach*, IRL Press, Oxford, UK). For example, for baculoviruses used in the experiments described below, the virus was plaque purified and amplified according to standard procedures (see, e.g., O'Reilly et al. *infra* and Summers and Smith, 1987, *A manual of methods for baculovirus vectors and insect cell culture procedures*, Texas Agricultural Experiment Station Bulletin No. 1555, College Station, Texas). AcMNPV and Sf21 cells were propagated by spinner culture in Hinks TNM-FH media (JRH Biosciences) containing 10% fetal bovine serum (FBS) and 0.1% PLURONIC F-68™. Amplified virus can be concentrated by ultracentrifugation in an SW28 rotor (24,000 rpm, 75 minutes) with a 27% (w/v) sucrose cushion in 5 mM NaCl, 10 mM Tris pH 7.5, and 10 mM EDTA. The viral pellet is then resuspended in phosphate-buffered saline (PBS) and sterilized by passage through a 0.45 µm filter (Nalgene). If desired, the virus may be resuspended

by sonication in a cup sonicator. AcMNPV was titered by plaque assay on Sf21 insect cells.

III. Examples of Expression of an Exogenous Gene in Mammalian Cells *In Vitro*

5        Nearly all mammalian cells are potential targets of non-mammalian viruses, and any cultured or primary cell can rapidly be tested. In the following example, the ability of the Z4 baculovirus to infect 19 different types of cells was tested. In this example, the baculovirus was the Z4 virus, prepared by homologous recombination of the Z4 transfer plasmid with linearized  
10      AcMNPV DNA. The tested cells were HepG2, Sk-Hep-1, NIH3T3, NIH3T3 cells expressing a cell-surface asialoglycoprotein receptor, HeLa, CHO/dhfr, 293, COS, Ramos, Jurkat, HL60, K-562, C<sub>2</sub>C<sub>12</sub> myoblasts, C<sub>2</sub>C<sub>12</sub> myotubes, primary human muscle myoblasts, Hep3B cells, FTO2B cells, Hepa1-6 cells, and nerve growth factor-differentiated PC12 cells.

15       Growth of Cells: Conventional tissue culture methods can be used to grow mammalian cells to be infected (Freshney, 1987, *Culture of Animal Cells: A Manual of Basic Techniques*, 2nd ed., Alan R. Liss, Inc. New York, NY). These cells were grown and infected as is described above. The cells were grown as follows. HepG2 and Sk-Hep-1 cells were cultured in minimal  
20      essential medium as modified by Eagle (EMEM) containing 10% FBS. NIH3T3, HeLa, 293, and COS cells were cultured in DMEM containing 10% FBS. CHO/dhfr cells were cultured in MEM alpha containing 10% FBS. Ramos, Jurkat, HL60, and K-562 cells were cultured in RPMI 1640 medium containing 10% FBS. HL60 cells were induced to differentiate by culture in  
25      the same medium containing 0.5% dimethyl sulfoxide and 1  $\mu$ M retinoic acid (Sigma). C<sub>2</sub>C<sub>12</sub> myoblasts were propagated in DMEM containing 20% FBS and differentiated to myotubes during culture in DMEM containing 10% horse serum. PC12 cells were propagated in DMEM containing 5% FBS and 10% horse serum, and were induced to differentiate during culture in DMEM  
30      containing 10% FBS, 5% horse serum, and 100 ng/ml nerve growth factor. All cells were seeded one day prior to infection with AcMNPV, and multiplicities

of infection were calculated assuming a doubling in cell number during this time. The C<sub>2</sub>C<sub>12</sub> and PC12 cells may have increased in cell number during differentiation, and therefore reflect a somewhat lower moi.

**5** In vitro Infection of Cells: *In vitro* infection of mammalian cells with a virus can be accomplished by allowing the virus to adsorb onto the cells for 0.1 to 6 hours; preferably, adsorption proceeds for 1 to 2 hours. Generally, a multiplicity of infection of 0.1 to 1,000 is suitable; preferably, the moi is 100 to 500. For relatively refractory cells, a moi of 100 to 1,000 is preferable. For the viruses used in the invention, the titer may be determined with conventional 10 methods which employ the non-mammalian cells that the virus naturally infects. If desired, the mammalian cell to be infected may be maintained on a matrix that contains collagen (e.g., rat tail Type I collagen). Based on cell counting after culture and infection of cells on collagen-coated plates and comparison with cells grown on a conventional EHS matrix, I have found that a collagen 15 matrix increases the susceptibility of cells (e.g., liver cells) to infection by a non-mammalian virus by 10 to 100 fold, relative to a conventional EHS matrix. Commercially-available plates containing a collagen matrix are available (e.g., BIO-COAT™ plates, Collaborative Research), and rat tail collagen is also commercially available (Sigma Chemical and Collaborative Research).

**20** In the *in vitro* assays described below, standard conditions for infection utilized 2 x 10<sup>6</sup> cells and RSV-lacZ AcMNPV at a moi of 15. Adherent cell lines were seeded one day prior to infection. Cells were exposed to virus in 2 ml of medium for 90 minutes, and then the virus-containing medium was removed and replaced with fresh medium. Mock-infected cells were treated 25 with 2 ml medium lacking the viral inoculum.

**30** Detection of Infection and Gene Expression: Delivery of a virus to a cell and expression of the exogenous gene can be monitored using standard techniques. For example, delivery of a virus (e.g., AcMNPV) to a cell can be measured by detecting viral DNA or RNA (e.g., by Southern or Northern blotting, slot or dot blotting, or *in situ* hybridization, with or without amplification by PCR). Suitable probes that hybridize to nucleic acids of the virus, regulatory sequences (e.g., the promoter), or the exogenous gene can be

conveniently prepared by one skilled in the art of molecular biology. Where the invention is used to express an exogenous gene in a cell *in vivo*, delivery of the virus to the cell can be detected by obtaining the cell in a biopsy. For example, where the invention is used to express a gene in a liver cell(s), a liver 5 biopsy can be performed, and conventional methods can be used to detect the virus in a cell of the liver.

Expression of an exogenous gene in a cell of a mammal can also be followed by assaying a cell or fluid (e.g., serum) obtained from the mammal for RNA or protein corresponding to the gene. Detection techniques commonly 10 used by molecular biologists (e.g., Northern or Western blotting, *in situ* hybridization, slot or dot blotting, PCR amplification, SDS-PAGE, immunostaining, RIA, and ELISA) can be used to measure gene expression. If desired, a reporter gene (e.g., *lacZ*) can be used to measure the ability of a particular baculovirus to target gene expression to certain tissues or cells. 15 Examination of tissue can involve: (a) snap-freezing the tissue in isopentane chilled with liquid nitrogen; (b) mounting the tissue on cork using O.C.T. and freezing; (c) cutting the tissue on a cryostat into 10  $\mu$ m sections; (d) drying the sections and treating them with 4% paraformaldehyde in PBS, followed by rinsing in PBS; (e) staining the tissue with X-gal (0.5 mg/ml)/ ferrocyanide (35 20 mM)/ ferricyanide (35 mM) in PBS; and (f) analyzing the tissue by microscopy.

To measure expression of the reporter gene in the infected cells, colorimetric assays of  $\beta$ -galactosidase enzymatic activity were performed with standard methods (Norton et al., 1985, Molecular & Cellular Biology 5:281-290). Other conventional methods for measuring  $\beta$ -galactosidase activity could 25 be used in lieu of the methods employed in this example. Cell extracts were prepared at one day post-infection. Cell monolayers were rinsed three times with PBS, scraped from the dish, and collected by low-speed centrifugation. The cell pellets were resuspended in 25 mM Tris pH 7.4/0.1 mM EDTA and then subjected to three cycles of freezing in liquid nitrogen and thawing in a 30 37°C water bath. The extracts were then clarified by centrifugation at 14,000 x g for 5 minutes. Standard conditions for assaying  $\beta$ -galactosidase activity utilized 0.1 ml of cell extract, 0.8 ml of PM-2 buffer, and 0.2 ml of o-

nitrophenyl- $\alpha$ -D-galactopyranoside (4 mg/ml) in PM-2 buffer for 10 minutes at 37°C (Norton et al., 1985, Mol. & Cell. Biol. 5:281-290). The reaction was stopped by the addition of 0.5 ml of 1 M sodium carbonate. The amount of substrate hydrolyzed was detected spectrophotometrically at 420 nm, and  $\beta$ -galactosidase enzymatic activity was calculated with conventional methods (Norton et al., 1985, Mol. & Cell. Biol. 5:281-290). The assay was verified to be linear with respect to extract concentration and time. Extract protein concentrations were determined using the Coomassie Plus protein assay (Pierce) with bovine serum albumin as a standard, and the level of  $\beta$ -galactosidase activity was expressed as units of  $\beta$ -galactosidase activity per mg of protein. Other standard protein assays can be used, if desired.

For histochemical staining of  $\beta$ -galactosidase activity, cells were fixed in 2% (w/v) formaldehyde-0.2% (v/v) paraformaldehyde in PBS for 5 minutes. After several rinses with PBS, the cells were stained by the addition of 0.5 mg/ml of X-gal (BRL) in PBS for 2-4 hours at 37°C.

Assay of 19 Mammalian Cell Types: The following examples illustrate that expression of an exogenous gene can be detected in 14 of the 19 mammalian cell types that were tested. These assays employed two different tests of  $\beta$ -galactosidase activity. By X-gal staining, the more sensitive assay, exogenous gene expression was detected in 14 of the 19 mammalian cell types. Using an ONPG assay of cell extracts, which is a less sensitive assay, three of the cell lines (HepG2, 293, and PC12) showed statistically significant ( $P<0.05$ , Student's t-test) higher  $\beta$ -galactosidase activity after exposure to the virus (Table 2). The human liver tumor line HepG2 exposed to the RSV-*lacZ* baculovirus expressed greater than 80-fold higher levels of  $\beta$ -galactosidase than did mock-infected controls. The adenovirus-transformed human embryonal kidney cell line 293 expressed the *lacZ* reporter gene at a level of about four-fold over background. In addition, PC12 cells, which were differentiated to a neuronal-like phenotype with nerve growth factor, exhibited about two-fold higher  $\beta$ -galactosidase levels after infection with the RSV-*lacZ* baculovirus. This difference was statistically significant ( $P=0.019$ ).

**TABLE 2. BACULOVIRUS-MEDIATED EXPRESSION OF AN RSV-LACZ REPORTER GENE IN MAMMALIAN CELL LINES.**

$\beta$ -galactosidase activity (units/mg)  
Mean  $\pm$  SD

Cell Line	Mock Infected	RSV- <i>lacZ</i> Virus
HepG2	0.030 $\pm$ 0.004	2.628 $\pm$ 0.729
Sk-Hep-1	0.019 $\pm$ 0.003	0.019 $\pm$ 0.004
NIH3T3	0.026 $\pm$ 0.003	0.023 $\pm$ 0.005
HeLa	0.034 $\pm$ 0.009	0.036 $\pm$ 0.005
CHO/dhfr-	0.020 $\pm$ 0.002	0.026 $\pm$ 0.005
293	0.092 $\pm$ 0.014	0.384 $\pm$ 0.024
COS	0.029 $\pm$ 0.002	0.032 $\pm$ 0.007
Ramos	0.008 $\pm$ 0.002	0.011 $\pm$ 0.004
Jurkat	0.012 $\pm$ 0.004	0.007 $\pm$ 0.001
HL60	0.042 $\pm$ 0.039	0.014 $\pm$ 0.015
K-562	0.018 $\pm$ 0.006	0.017 $\pm$ 0.002
C <sub>2</sub> C <sub>12</sub> myoblast	0.015 $\pm$ 0.001	0.014 $\pm$ 0.003
C <sub>2</sub> C <sub>12</sub> myotube	0.049 $\pm$ 0.011	0.042 $\pm$ 0.004
PC12 (+NGF)	0.019 $\pm$ 0.005	0.033 $\pm$ 0.004

20 By histochemical staining, a more sensitive assay,  $\beta$ -galactosidase activity was detected in 14 of the 19 cell lines exposed to virus. Thus, certain of the cell lines that did not yield statistically significantly higher levels of  $\beta$ -galactosidase, as measured in extracts, were, in fact, able to express  $\beta$ -galactosidase at low, but reproducible, frequencies, as detected by the more sensitive X-gal staining procedure. This frequency could be increased by using higher multiplicities of infection such that cells that, at a low moi appear not to express the gene, stain blue at a higher moi. Examples of cell lines that could be transfected in this manner include SK-Hep-1, NIH3T3, HeLa, CHO/dhfr, 293, Cos, and C<sub>2</sub>C<sub>12</sub> cells. In addition,  $\beta$ -galactosidase activity was detected in 30 primary human muscle myoblasts that were exposed to virus. This finding indicates that baculovirus was able to mediate gene transfer both to primary

cells and the corresponding established cell line (C<sub>2</sub>C<sub>12</sub>), indicating that expression of the exogenous gene in an established cell line has predictive value for the results obtained with primary cells.

5         $\beta$ -galactosidase activity was also detected in Hep3B cells treated with the virus; the level of expression in these cells was nearly equivalent to the level detected with HepG2 cells. In addition,  $\beta$ -galactosidase activity was found in FTO2B (rat hepatoma) cells and Hepa1-6 (human hepatoma) cells exposed to virus.  $\beta$ -galactosidase activity was also detected in NIH3T3 cells that were engineered to express the asialoglycoprotein receptor on the cell surface. These 10      cells expressed approximately two times the level of  $\beta$ -galactosidase as did normal NIH3T3 cells. This observation suggests that an asialoglycoprotein receptor may be used to increase susceptibility to viral-mediated gene transfer.

15      At the moi employed, the Ramos, Jurkat, HL60, and K-562 cell lines did not express statistically significant levels of  $\beta$ -galactosidase, as revealed by  $\beta$ -galactosidase enzyme assays after infection. Based on the results with other mammalian cell lines, it is expected that  $\beta$ -galactosidase activity would be detected in these apparently refractory cell lines when a higher dose (i.e., moi) of virus or longer adsorption time period is utilized.

20      Even when exposure of cells to the virus results in expression of the exogenous gene in a relatively low percentage of the cells (*in vitro* or *in vivo*), the invention can be used to identify or confirm the cell- or tissue-type specificity of the promoter that drives expression of the exogenous gene (e.g., a reporter gene such as a chloramphenicol acetyltransferase gene, an alkaline phosphatase gene, a luciferase gene, or a green fluorescent protein gene). Once 25      identified, such a promoter may be employed in any of the conventional methods of gene expression. Similarly, only relatively low levels of expression are necessary for provoking an immune response (i.e., produce antibodies) in a mammal against the heterologous gene product. Thus, the gene expression method of the invention can be used in the preparation of antibodies against a 30      preferred heterologous antigen by expressing the antigen in a cell of a mammal. Such antibodies may be used *inter alia* to purify the heterologous antigen. The gene expression method may also be used to elicit an immunoprotective

response in a mammal (i.e., be used as a vaccine) against a heterologous antigen. In addition, the invention can be used to make a permanent cell line from a cell in which the virus mediated expression of a cell-immortalizing sequence (e.g., SV40 T antigen).

5        Histochemical staining using X-gal provided a highly sensitive method for detecting  $\beta$ -galactosidase expression in cells exposed to the modified AcMNPV. When HepG2 cells were exposed to the modified AcMNPV at a moi of 15, about 5-10% of the cells stained with X-gal (Fig. 14A). At a multiplicity of infection (moi) of 125, about 25-50% of the cells were stained  
10      (Fig. 14B). No adverse effects of exposure to the virus, such as nuclear swelling, were observed. These data demonstrate that the modified AcMNPV is highly effective at gene transfer into HepG2 cells when a sufficient dose of virus is used. When the Sk-Hep-1 line was exposed to virus at a moi of 15, no stained cells were observed (data not shown). While the majority of Sk-Hep-1  
15      cells that were exposed to virus at a moi of 125, did not stain blue (Fig. 14C), a few cells were found that stained darkly after treatment with this higher doses of virus (Fig. 14D). These data indicate that cells that appear to be refractory to the virus at a relatively low moi can, in fact, be infected, and express the exogenous gene, at a higher moi. Stained cells were not found in mock-  
20      infected cultures (data not shown). The frequency of stained cells in the Sk-  
Hep-1 cell line was estimated to be 2,000-4,000 fold less than in HepG2 cells after exposure to equivalent doses of the modified virus, as determined by cell counting. Thus, the cell type-specificity demonstrated by the modified  
25      AcMNPV is relative rather than absolute. These data also indicate that, where a mixture of cells is contacted with the virus (*in vitro* or *in vivo*), the dosage of the virus can be adjusted to target the virus to the cells that are infected at a lower moi.

30      Expression in Primary Cultures of Rat Hepatocytes: This example illustrates that a non-mammalian DNA virus can also be used to express an exogenous gene at high levels in primary cultures of rat hepatocytes. In this experiment, freshly prepared rat hepatocytes were plated onto dishes coated with rat tail collagen as previously described (Rana et al., 1994, Mol. Cell.

Biol. 14:5858-5869). After 24 hours, the cells were fed with fresh medium containing RSV-*lacZ* baculovirus at a multiplicity of infection of approximately 430. After an additional 24 hours, the cells were fixed and stained with X-gal. Over 70% of the cells were stained blue, indicating that they have taken up and 5 expressed the RSV-*lacZ* cassette (Fig. 15). The frequency of expression obtained in this example is higher than the frequency reported with conventional viral vectors used in gene therapy (e.g., retroviral and Herpes Simplex Virus vectors). Mock-infected cultures did not contain any positively-stained cells (data not shown). Other preferred exogenous genes can be used in 10 lieu of the *lacZ* gene. In addition, other primary cells can readily be plated and incubated with a non-mammalian cell in lieu of the primary rat hepatocytes.

15 Expression in Cortex Cultures: The following two examples illustrate that a non-mammalian DNA virus can be used to express an exogenous gene in cultured neuronal and glial cells. For this example, the Z4 virus was prepared from Sf9 cells grown in Hink's TNM-FH media containing 10% FCS, as described above. The virus was purified by banding on a 20-60% sucrose gradient in phosphate-buffered saline. The titer of the virus employed in the following experiments was  $3 \times 10^8$  pfu/ml (for virus stock #1) or  $2 \times 10^9$  pfu/ml (for virus stock # 2), as measured on Sf9 cells. Each virus stock was 20 sonicated prior to use.

25 For the first example, rat cerebral cortex cultures were prepared from E16 embryonic pups. A 24-well dish was seeded with 300,000 cells/well, and, at 4 days post-plating, the cells were infected by adding varying amounts of virus in serum-containing medium to the wells, as is indicated in Table 3. The virus was allowed to adsorb onto the cells for 24 hours.

TABLE 3. EXPRESSION OF AN EXOGENOUS GENE IN RAT CORTICAL CELLS.

<u>VIRUS</u>	1 $\mu$ l	2 $\mu$ l	5 $\mu$ l	10 $\mu$ l	50 $\mu$ l	100 $\mu$ l
Z4 Stock #1	moi = 1	moi = 2	moi = 5	moi = 10	moi = 50	moi = 100
	no blue cells	no blue cells	~5 blue cells	~20 blue cells	~500 blue cells	~2200 blue cells (~0.75%)
Z4 Stock #2	moi = 6.7	moi = 13.3	moi = 34	moi = 67	moi = 335	moi = 667
	few blue cells	~100 blue cells	~200 blue cells	~450 blue cells	~1000 blue cells	~1300 blue cells
PBS				no blue cells	no blue cells	no blue cells

5 Expression of the exogenous  $\beta$ -galactosidase gene was measured by counting the number of blue cells after staining the cells with X-gal. Table 3 provides the number of blue cells observed in five fields of the microscope at 10X magnification; each well contained approximately 65 fields. In some wells, the 10 cells at the periphery of the well were preferentially stained.

15 These data indicate that the exogenous  $\beta$ -galactosidase gene was expressed from the virus in the cultured neuronal cells. In contrast, no blue cells were detected when the cell cultures were mock-infected with PBS. Thus, this non-mammalian virus can be used to express an exogenous gene in neuronal and glial cells, as determined by the detection of blue cells that were, by cell morphology, identified as neurons and glia according to standard criteria.

20 In the second example, the Z4 baculovirus was used to express an exogenous gene in cultured cortical cells obtained from rat pups at the E20 and P1 stages. The cells from E20 pups were plated in 24-well dishes at 380,000 cells/well. The cells from P1 pups were plated at 300,000 cells/well. The E20 cultures were treated with araC (to inhibit the growth of glia) at 6 days post-plating, and they were infected at 10 days post-plating. The P1 cultures were treated with araC at 2 days post-plating, and they were infected at 6 days post-plating. Samples of each culture were infected with various dilutions of Z4 25 virus at titer  $2 \times 10^9$  pfu/ml. To measure the strength of the RSV promoter, the cells were also infected, in separate experiments, with Herpes Simplex Virus

(HSV) expressing the *lacZ* gene under two different promoters. In one case, cells were infected with a HSV in which the *lacZ* gene was placed under the control of an RSV promoter. The titer of this HSV stock was  $2 \times 10^7$  IU/ml, as measured on PC12 cells with X-gal histochemistry. For comparison, the cells 5 were infected with a HSV in which the *lacZ* gene was placed under control of the HSV IE4/5 promoter. The titer of this virus was  $2 \times 10^8$  IU/ml, as measured on PC12 cells with X-gal histochemistry. For a negative control, the cells were mock-infected with PBS. Expression of the exogenous *lacZ* gene 10 was measured by counting the number of blue cells obtained upon staining the cells with X-gal.

The non-mammalian Z4 virus of the invention successfully expressed the exogenous *lacZ* gene in cultured cortical cells obtained from rat pups at both the E20 and P1 stages of development. With 1-100  $\mu$ l of the Z4 virus, 4.9-10% of the cortical cells at the E20 stage, and 2.1-5.75% of the cortical cells at 15 the P1 stage, were stained blue with X-gal, indicating expression of the exogenous gene in those cells. Of the cells infected with 0.1-5.0  $\mu$ l of the HSV RSVlacZ virus, as a positive control, 1.9-3.4% of the E20 cells, and 0.45-4.2% of the P1 cells stained blue with X-gal. When the cells were infected with a 5  $\mu$ l sample of HSV expressing *lacZ* from the IE4/5 promoter, nearly 100% of 20 the cells stained blue. When E20 or P1 cortical cells were mock-infected with PBS, as a negative control, no blue cells were detected. These data provide additional evidence that the non-mammalian Z4 baculovirus can be used to express an exogenous gene in cortex cells. These data also indicate that the level of expression obtained with the Z4 virus is comparable to the level of 25 expression obtained with HSV.

Dose-response of Baculovirus-mediated Gene Transfer: The histochemical data presented above indicate that increasing amounts of  $\beta$ -galactosidase are produced after exposure of mammalian cells to increasing amounts of virus. To quantitate the dose-dependence of baculovirus-mediated 30 gene expression, HepG2 cells were exposed to increasing doses of virus and assayed for  $\beta$ -galactosidase enzyme activity. The amount of enzyme produced was linearly related to the inoculum of virus used over a wide range of doses

(Fig. 16). This suggests that entry of each virus particle occurs independently of entry of other virus particles. The maximum dose of virus used in this assay was limited by the titer and volume of the viral stock, and no plateau in the amount of expression was observed using higher doses of virus. Accordingly, 5 these data indicate that, in practicing the invention, one can modulate the level expression (i.e., the percent of cells in which the exogenous gene is expressed) by adjusting the dosage of virus used.

Time Course of Baculovirus-mediated Gene Transfer: HepG2 cells were exposed to the RSV-*lacZ* virus for 1 hour, after which the cells were harvested 10 at various times and quantitatively assayed for  $\beta$ -galactosidase activity. As is shown in Fig. 17,  $\beta$ -galactosidase activity was detected as early as 6 hours after exposure to the virus, and expression peaked 12-24 hours post-infection. As is expected for an episomal DNA molecule, expression from the RSV-*lacZ* cassette gradually subsided at later time (Fig. 17 and data not shown). LacZ 15 expression remained detectable by X-gal staining at 12 days post-transfection in fewer than 1 in 1,000 cells (data not shown). This expression of LacZ was not the result of viral spread, because culture supernatants taken from HepG2 cells 10 days post-infection had titers of 10 pfu/ml as determined by plaque assay on Sf21 cells. These data suggest that, where the invention is used in the manufacture of proteins that are purified from HepG2 cells, it may be desirable 20 to isolate the protein from the cell at a time not sooner than 6 hours after infection of the cell. Depending on the half-life of the protein, it may be desirable to isolate the protein shortly after the peak in protein expression (i.e., after approximately 22-26 hours (e.g., approximately 24 hours) post-infection 25 for HepG2 cells). The optimal time period for maximizing isolating the manufactured protein can readily be determined for each protein, virus, and cell.

Expression Occurs *De Novo* in Mammalian Cells: These examples 30 confirm that expression of the exogenous gene occurs *de novo* in mammalian cells. To demonstrate that the detected reporter gene activity in the mammalian cells was not simply the result of  $\beta$ -galactosidase being physically associated with AcMNPV virions as they enter the mammalian cell, several experiments

were performed that demonstrate that the observed expression of the *lacZ* reporter gene was the result of *de novo* synthesis of  $\beta$ -galactosidase. First, the RSV-*lacZ* virus inoculum was assayed for  $\beta$ -galactosidase activity, and the level of  $\beta$ -galactosidase activity was found to be less than 10% of that expressed 5 after infection of HepG2 cells. Second, HepG2 cells were infected with the RSV-*lacZ* virus and then cultured in the presence of the protein synthesis inhibitor cycloheximide. Inclusion of cycloheximide after infection inhibited the accumulation of  $\beta$ -galactosidase enzyme activity by more than 90% (Table 4). Third, HepG2 cells were infected at an equivalent moi with BacPAK6 10 (Clontech), a baculovirus in which the *lacZ* gene was under control of the viral polyhedrin promoter rather than the RSV promoter (Table 4). The latter virus expresses extremely high levels of  $\beta$ -galactosidase activity in insect cells where the promoter is active (data not shown). In mammalian cells, the viral polyhedrin promoter is inactive, and the virus containing this promoter failed to 15 provide any enzyme activity in mammalian cells (Table 4). In contrast to prior studies of baculovirus interactions with mammalian cells, these data demonstrate that *de novo* synthesis of *lacZ* occurs after baculovirus-mediated gene transfer into a mammalian cell.

TABLE 4. BACULOVIRUS-MEDIATED GENE EXPRESSION OCCURS *DE NOVO*.

20	Virus	Drug During Infection	Drug Post Infection	$\beta$ -galactosidase (% of RSV- <i>lacZ</i> , mean $\pm$ SD)
	RSV- <i>lacZ</i>	none	none	100 $\pm$ 5.8
	none	none	none	3.2 $\pm$ 0.4
25	RSV- <i>lacZ</i>	none	cycloheximide	10.3 $\pm$ 1.0
	BacPAK6	none	none	2.8 $\pm$ 0.4
	RSV- <i>lacZ</i>	chloroquine	chloroquine	2.9 $\pm$ 0.1
	RSV- <i>lacZ</i>	none	chloroquine	25.1 $\pm$ 6.2

Baculovirus-mediated Gene Transfer is Inhibited by Lysomotropic Agents:

To gain insight into the mechanism by which baculoviruses express an exogenous gene in a mammalian cell, the susceptibility of gene expression to a lysomotropic agent was examined. Like other enveloped viruses, the budded form of AcMNPV normally enters cells via endocytosis, followed by low pH-triggered fusion of the viral envelope with the endosomal membrane, thus allowing escape into the cytoplasm (Blissard et al., 1993, *J. Virol.* 66:6829-6835; Blissard et al., 1990, *Ann. Rev. of Entomol.* 35:127-155). To determine whether endosome acidification was necessary for baculovirus-mediated gene transfer into mammalian cells, HepG2 cells were infected with RSV-*lacZ* AcMNPV in the presence of chloroquine, a lysomotropic agent. HepG2 cells were exposed to AcMNPV virus in media containing or lacking inhibitor for 90 minutes, then the virus-containing media were removed and replaced with fresh media containing or lacking inhibitors as listed.

At one day post-infection, the cells were harvested and extracts were assayed for  $\beta$ -galactosidase activity and protein content. Each value in the table represents the average of three independent assays, with the amount of  $\beta$ -galactosidase produced by the RSV-*lacZ* AcMNPV virus in the absence of inhibitors assigned a value of 100%.  $\beta$ -galactosidase activity was normalized for protein content of each extract. When 25  $\mu$ M chloroquine was continuously present during and after exposure of HepG2 cells to the virus, *de novo* expression of  $\beta$ -galactosidase was completely prevented (Table 4). This suggests that baculovirus-mediated gene transfer is dependent upon endosomal acidification. When chloroquine was added to the cells at 90 minutes after exposure to the virus, only partial inhibition of  $\beta$ -galactosidase expression was observed. Apparently, a portion ( $\approx$ 22%) of the viral particles were able to proceed through the endosomal pathway during the 90 minutes of exposure to the virus.

Baculovirus-mediated Gene Transfer is Enhanced by Butyrate: This example illustrates that butyrate enhances the ability of a baculovirus to express an exogenous gene in a mammalian cell. Five transfer plasmids containing different mammalian promoters were created, as diagrammed in Fig. 18. These

vectors were constructed using pSV/BV, a modified version of the baculovirus transfer plasmid pBacPAK9 (Clontech), containing an altered polylinker and SV40 splice and polyadenylation signals. pSV/BV was constructed by restriction of pBacPAK9 with *Not*I, treatment with T4 DNA polymerase to create blunt ends, and self-ligation to remove the *Not*I site. A new *Not*I site was then added by ligation of the linker pGCGGCCGC into the *Sma*I site. Finally, SV40 splice and polyadenylation sequences were added by digestion of a variant of pRSVglobin with *Bgl*II-*Bam*HI, and insertion of the 850 bp fragment into the *Bam*HI site of the modified BacPAK9, yielding pSV/BV.

5 The human cytomegalovirus immediate early promoter, 758 bp *Hind*III-*Xba*I fragment, was excised from pCMV-EBNA (Invitrogen) at *Hind*III, *Bam*HI and inserted into the *Hind*III, *Bam*HI sites of pBluescript (SKII<sup>+</sup>), yielding plasmid pCMV-SKII<sup>+</sup>. The promoter was then excised from CMV-SK II<sup>+</sup> at the *Xho*I, *Bam*HI sites and inserted into the *Xho*I, *Bgl*II sites of pSV/BV, yielding plasmid pCMV/BV. The 500 bp mouse phosphoglycerate kinase (PGK) promoter was prepared by cutting pKJ1-neo (Tybulewicz et al., 1991, Cell 65: 1153-1163) with *Eco*RI and made blunt with T4 DNA polymerase to remove the *Eco*RI site. The resulting pKJ1 plasmid lacking the *Eco*RI site was amplified by pfu polymerase chain reaction using the primers

10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845

Recombinant viruses were generated by cotransfection of the baculovirus transfer vectors with linear BP6 viral DNA (Clontech) into Sf21

cells. The recombinant viruses were purified through three rounds of plaque isolation and amplified on Sf21 cells. The amplified viruses were concentrated by ultracentrifugation as described above and titered by a 96-well method on Sf21 insect cells (O'Reilly et al., 1992, *Baculovirus Expression Vectors: A Laboratory Manual*, W.H. Freeman, New York, NY).

The human hepatocellular carcinoma cell line HepG2 was infected with each recombinant virus at a multiplicity of infection of 100. Two million cells were infected in a final volume of 1 ml Eagle's Minimum Essential Medium in a 60 mm tissue culture dish. The infection was allowed to proceed for two hours, then 4 ml of complete medium was added to the cells. In a second series of HepG2 infections, the conditions of the first infections were repeated with the exception that after the infection had proceeded for 2 hours 25  $\mu$ l of sodium butyrate (100 mM) was added to the cells with 1.5 ml complete media. As a control, cells were mock-infected to assess background  $\beta$ -galactosidase enzyme activity. The cell monolayers were collected after 24 hours and prepared for a colorimetric assay (with ONPG) of  $\beta$ -galactosidase enzymatic activity as described above. Hepatocytes were isolated by collagenase perfusion and plated on rat tail collagen as previously described (Boyce et al., 1996, Proc. Natl. Acad. Sci. 93:2348-2352). Assay conditions (time and amount of extract used) were varied to be within the linear range of the assay. The amount of product was determined by spectrophotometry and  $\beta$ -galactosidase enzyme activity was calculated. The Coomassie Plus protein assay (Pierce) was used to determine the protein concentration of the extracts, and results were expressed as units of  $\beta$ -galactosidase normalized to total protein content of the extract. The amount of background activity from the mock-infected cells was subtracted from the total amount of enzyme activity for each of the promoters. Each infection was performed in triplicate, and expressed as the mean average with standard deviation (Table 5).

As shown in Table 5, the incorporation of viral or mammalian cellular promoters into baculoviruses allows for expression of an exogenous gene product in mammalian cells. The CMV promoter led to the highest level of  $\beta$ -galactosidase activity, with the RSV and  $\beta$ -actin promoters producing lower

levels of  $\beta$ -galactosidase activity. At the moi of virus employed in this example, the albumin and PGK promoters showed no activity above background levels in extracts of cells that were not treated with butyrate, although positively stained cells were detected by X-gal staining. The addition 5 of sodium butyrate to the cells after infection led to detectable levels of  $\beta$ -galactosidase expression with all of the promoters tested. After treating cells with sodium butyrate, the CMV promoter showed a five-fold increase in expression of the  $\beta$ -galactosidase reporter gene. The RSV LTR, albumin, pGK1, and  $\beta$ -actin promoters all led to increased gene expression after 10 treatment with butyrate. Without being bound to any particular theory, it is postulated that sodium butyrate increases cellular differentiation and histone acetylation, which increases transcription.

**TABLE 5. COMPARISON OF VARIOUS PROMOTER STRENGTHS WITH AND WITHOUT SODIUM BUTYRATE**

15

	Hep G2	Hep G2	Rat Hepatocytes
Promoter	-butyrate	+butyrate	-butyrate
CMV	17 $\pm$ 1.4 <sup>a</sup>	86 $\pm$ 33	18 $\pm$ 1.2
RSV	1.0 $\pm$ 0.1	2.2 $\pm$ 0.1	0.25 $\pm$ 0.11
pGK1	0.0 $\pm$ 0.0	0.02 $\pm$ 0.02	0.64 $\pm$ 0.58
20 Albumin	0.0 $\pm$ 0.0	0.08 $\pm$ 0.04	0.15 $\pm$ 0.08
$\beta$ -actin	0.1 $\pm$ 0.01	0.05 $\pm$ 0.02	0.25 $\pm$ 0.07

<sup>a</sup> Promoter strength is expressed in Units/mg of  $\beta$ -galacto-sidase.

Analysis of RNA Expression From Viral Promoters in HepG2 Cells:

One advantage of using a non-mammalian virus to express an exogenous gene 25 in a mammalian cell is that, due to a lack of appropriate host cell factors, the non-mammalian viral promoters may not be active in the mammalian cell. To determine whether AcMNPV viral gene are expressed in HepG2 cells, the viral RNA was analyzed. In these experiments, HepG2 cells were infected with the Z4 virus at a moi of approximately 30. At 18 hours post-infection, the cells

were harvested, and total cellular RNA was extracted from the cells. The total cellular RNA was analyzed by Northern blotting for expression of viral genes. The probe included a 1.7 kbp *PacI-SalI* fragment from pAcUW1 (Pharmingen) which contains the viral late gene, p74, as well as the very late 5 (hyperexpressed) gene, p10. Total cellular RNA from Z4-infected Sf9 insect cells was employed as a positive control. While extremely strong signals were detected for p10 and p74 for the control insect cells, no signal was observed for Z4-infected HepG2 cells or uninfected control cells.

Additional experiments that used reverse transcriptase-PCR (RT-PCR), a 10 highly sensitive method, provided further evidence that the majority of viral genes are not transcribed in the mammalian HepG2 cells. RT-PCR analysis was performed with RNA prepared from Z4-infected HepG2, uninfected HepG2, or infected Sf9 cells at 6 or 24 hours post-infection. HepG2 cells were infected at a moi of 10 or 100. At 6 hours post-infection, no RT-PCR product 15 was observed from the viral p39, ETL, LEF1, IE1, or IE-N genes at either dose of virus in Z4-infected HepG2 cells. In contrast, RT-PCR products were readily detected in Z4-infected Sf9 cells. At 24 hours post-infection, no expression of these gene was detected in HepG2 cells infected at a moi of 10. At 24 hours post-infection, no expression of the viral p39, ETL, or LEF1 genes 20 was observed in HepG2 cells infected at an moi of 100. However, at this high does of virus, low levels of expression from the viral IE1 and IE-N genes was observed. The low level of expression detected at an moi of 100 was nonetheless significantly lower than the level of expression in insect cells.

Expression of these genes may result from recognition of the viral TATA 25 box by mammalian transcription factors (i.e., transcription of the immediate early genes by RNA polymerase II (see, e.g., Hoopes and Rorhman, 1991, Proc. Natl. Acad. Sci. 88:4513-4517). In contrast to the immediate early genes, the late or very late viral genes are transcribed by a virally-encoded RNA polymerase that, instead of requiring a TATA box, initiates transcription at a 30 TAAG motif (O'Reilly et al., *supra*). Accordingly, expression of the viral late or very late genes is naturally blocked in mammalian cells. If desired,

expression of the immediate early genes can be blocked by deleting those genes, using conventional methods.

While certain viruses have an intrinsic ability to infect liver cells, infection of liver cells by other viruses may be facilitated by a cellular receptor, such as a cell-surface asialoglycoprotein receptor (ASGP-R). HepG2 cells differ from Sk-Hep-1 human hepatocytes and NIH3T3 mouse fibroblast cells by the presence of ASGP-R on the cell surface. In certain of the above experiments,  $\beta$ -galactosidase was expressed in fewer Sk-Hep-1 cells (Fig. 14B) or NIH3T3 cells than HepG2 cells. The *lacZ* gene was expressed in HepG2 cells at a frequency estimated as greater than 1,000 fold more than that in Sk-Hep-1 cells, based on quantitative counts of X-gal stained cells. Normal hepatocytes have 100,000 to 500,000 ASGP-R, with each receptor internalizing up to 200 ligands per day. The ASGP-R may facilitate entry of the virus into the cell by providing a cell-surface receptor for glycoproteins on the virion.

The glycosylation patterns of insect and mammalian cells differ, with the carbohydrate moieties on the surface of the virion produced in insect cells lacking terminal sialic acid. Those carbohydrate moieties may mediate internalization and trafficking of the virion. In addition to the ASGP-R, other galactose-binding lectins that exist in mammals (see, e.g., Jung et al., 1994, *J. Biochem. (Tokyo)* 116:547-553) may mediate uptake of the virus.

If desired, the cell to be infected can be modified to facilitate entry of the baculovirus into the cell. For example, ASGP-R can be expressed on the surface of a cell to be infected by the virus (e.g., baculovirus). The genes encoding the ASGP-R have been cloned (Spiess et al., 1985, *J. Biol. Chem.* 260:1979 and Spiess et al., 1985, *Proc. Natl. Acad. Sci.* 82:6465), and standard methods (e.g., retroviral, adeno-associated virus, or adenoviral vectors or chemical methods) can be used for expression of the ASGP-R in the cell to be infected by a virus. Other suitable mammalian lectins can be substituted for the ASGP-R in such methods (see, e.g., Ashwell et al., 1982, *Ann. Rev. Biochem.* 51:531-534). Other receptors for ligands on the virion, such as receptors for insect carbohydrates or the CD4 receptor for HIV, can also be expressed on the

surface of the mammalian cell to be infected to facilitate infection (see, e.g., Monsigny et al., 1979, Biol. Cellulaire 33:289-300).

Entry into the cell also can be facilitated by modifying the virion, e.g., through chemical means, to enable the virion to bind to other receptors on the mammalian cell (see, e.g., Neda, et al., 1991, J. Biol. Chem. 266:14143-14146 and Burns et al., 1993, Proc. Natl. Acad. Sci. 90:8033-8037). Alternatively, the glycosylation patterns and levels of baculovirus can be modified by growing the virus on Ea4 cells, which are derived from *Estigmene acrea* (e.g., as described by Rooney et al. in Nature Biotech). In addition, one can modify the virus such that it expresses mammalian glycosylation enzymes (Jarvis et al., 1996, Nature Biotech. 14:1288-1292).

#### IV. Therapeutic Use of a Non-mammalian DNA Virus Expressing an Exogenous Gene

The discovery that a non-mammalian DNA virus efficiently expressed a lacZ reporter gene in several mammalian cells indicates that a non-mammalian DNA virus can be used therapeutically to express an exogenous gene in a cell of a mammal. For example, the method of the invention can facilitate expression of an exogenous gene in a cell of a patient for treatment of a disorder that is caused by a deficiency in gene expression. Numerous disorders are known to be caused by single gene defects (see Table 6), and many of the genes involved in gene deficiency disorders have been identified and cloned. Using standard cloning techniques (see, e.g., Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, (1989)), a non-mammalian virus can be engineered to express a desired exogenous gene in a mammalian cell (e.g., a human cell).

**TABLE 6. EXAMPLES OF DISORDERS THAT CAN BE TREATED WITH THE INVENTION AND GENE PRODUCTS THAT CAN BE MANUFACTURED WITH THE INVENTION**

<b>Gene Product</b>	<b>Disorder</b>
fumarylacetoacetate hydrolase	hereditary tyrosinemia
30 phenylalanine hydroxylase	phenylketonuria

Gene Product	Disorder
LDL receptor	familial hypercholesterolemia
alpha-1 antitrypsin	alpha-1 antitrypsin deficiency
glucose-6-phosphatase	glycogen storage diseases
porphobilinogen deaminase	diseases caused by errors in porphyrin metabolism, e.g., acute intermittent porphyria
5 CPS-I, OTC, AS, ASL, or arginase	disorders of the urea cycle
factors VIII & IX	hemophilia
cystathione $\beta$ -synthase	homocystinuria
branched chain ketoacid decarboxylase	maple syrup urine disease
albumin	hypoalbuminemia
10 isovaleryl-CoA dehydrogenase	isovaleric acidemia
propionyl CoA carboxylase	propionic acidemia
methyl malonyl CoA mutase	methylmalonyl acidemia
glutaryl CoA dehydrogenase	glutaric acidemia
insulin	insulin-dependent diabetes
15 $\beta$ -glucosidase	Gaucher's disease
pyruvate carboxylase	pyruvate carboxylase deficiency
hepatic phosphorylase or phosphorylase kinase	glycogen storage diseases
glycine decarboxylase, H-protein, or T-protein	non-ketotic hyperglycinemias
Wilson's disease copper-transporting ATPase	Wilson's disease
20 Menkes disease copper-transporting ATPase	Menkes disease
cystic fibrosis transmembrane conductance regulator	cystic fibrosis

The invention can also be used to facilitate the expression of a desired gene in a cell having no obvious deficiency. For example, the invention can be used to express insulin in a hepatocyte of a patient in order to supply the patient with insulin in the body. Other examples of proteins that can be expressed in a mammalian cell (e.g., a liver cell) for delivery into the system circulation of the mammal include hormones, growth factors, and interferons. The invention can also be used to express a regulatory gene or a gene encoding a transcription factor (e.g., a VP16-tet repressor gene fusion) in a cell to control the expression of another gene (e.g., genes that are operably-linked to a tet

operator sequence; see, e.g., Gossen et al., 1992, Proc. Natl. Acad. Sci. 89:5547-5551). In addition, the invention can be used in a method of treating cancer by expressing in a cell a cancer therapeutic gene, such as a gene encoding a tumor suppressor (e.g., p53), tumor necrosis factor, thymidine kinase, diphtheria toxin chimera, or cytosine deaminases (see, e.g., Vile and Russell, 1994, Gene Therapy 1:88-98).

Other useful gene products include RNA molecules for use in RNA decoy, antisense, or ribozyme-based methods of inhibiting gene expression (see, e.g., Yu et al., 1994, Gene Therapy 1:13-26). If desired, the invention can be used to express a gene, such as cytosine deaminase, whose product will alter the activity of a drug or prodrug, such as 5-fluorocytosine, in a cell (see, e.g., Harris et al., 1994, Gene Therapy 1: 170-175). Methods such as the use of ribozymes, antisense RNAs, transdominant repressors, polymerase mutants, or core or surface antigen mutants can be used to suppress hepatitis viruses (e.g., hepatitis virus A, B, C, or D) in a cell. Other disorders such as familial hemachromatosis can also be treated with the invention by treatment with the normal version of the affected gene.

Preferred genes for expression include those genes that encode proteins that are expressed in normal mammalian cells (e.g., hepatocytes or lung cells). For example, genes encoding enzymes involved in the urea cycle, such as the genes encoding carbamoyl phosphate synthetase (CPS-I), ornithine transcarbamylase (OTC), arginosuccinate synthetase (AS), arginosuccinate lyase (ASL), and arginase are useful in this method. All of these genes have been cloned (for OTC, see Horwich et al., 1984, Science 224:1068-1074 and Hata et al., 1988, J. Biochem (Tokyo) 103:302-308; for AS, see Bock et al., 1983, Nucl. Acids Res. 11:6505; Surh et al., 1988, Nucl. Acids Res. 16:9252; and Dennis et al., 1989, Proc. Natl. Acad. Sci. 86:7947; for ASL, see O'Brien et al., 1986, Proc. Natl. Acad. Sci. 83:7211; for CPS-I, see Adcock et al., 1984, (Abstract) Fed. Proc. 43:1726; for arginase, see Haraguchi et al., Proc. Natl. Acad. Sci. 84:412). Subcloning these genes into a baculovirus can be readily accomplished with common techniques.

The therapeutic effectiveness of expressing an exogenous gene in a cell can be assessed by monitoring the patient for known signs or symptoms of a disorder. For example, amelioration of OTC deficiency and CPS deficiency can be detected by monitoring plasma levels of ammonium or orotic acid.

5       Similarly, plasma citrulline levels provide an indication of AS deficiency, and ASL deficiency can be followed by monitoring plasma levels of arginosuccinate. Parameters for assessing treatment methods are known to those skilled in the art of medicine (see, e.g., Maestri et al., 1991, *J. Pediatrics*, 119:923-928).

10       The non-mammalian DNA virus (e.g., baculovirus) can be formulated into a pharmaceutical composition by admixture with a pharmaceutically acceptable non-toxic excipient or carrier (e.g., saline) for administration to a mammal. In practicing the invention, the virus can be prepared for use in parenteral administration (e.g., for intravenous injection (e.g., into the portal vein)), intra-arterial injection (e.g., into the femoral artery or hepatic artery), intraperitoneal injection, intrathecal injection, or direct injection into a tissue or organ (e.g., intramuscular injection). In particular, the non-mammalian virus can be prepared in the form of liquid solutions or suspensions in conventional excipients. The virus can also be prepared for intranasal or intrabronchial administration, particularly in the form of nasal drops or aerosols in conventional excipients. If desired, the virus can be sonicated in order to minimize clumping of the virus in preparing the virus.

20       In practicing the invention, the virus can be used to infect a cell outside of the mammal to be treated (e.g., a cell in a donor mammal or a cell *in vitro*), and the infected cell then is administered to the mammal to be treated. In this method, the cell can be autologous or heterologous to the mammal to be treated. For example, an autologous hepatocyte obtained in a liver biopsy can be used (see, e.g., Grossman et al., 1994, *Nature Genetics* 6:335). The cell can then be administered to the patient by injection (e.g., into the portal vein). In 25 such a method, a volume of hepatocytes totaling about 1% - 10% of the volume of the entire liver is preferred. Where the invention is used to express an 30 exogenous gene in a liver cell, the liver cell can be delivered to the spleen, and

the cell can subsequently migrate to the liver *in vivo* (see, e.g., Lu et al., 1995, Hepatology 21:7752-759). If desired, the virus may be delivered to a cell by employing conventional techniques for perfusing fluids into organs, cells, or tissues (including the use of infusion pumps and syringes). For perfusion, the 5 virus is generally administered at a titer of  $1 \times 10^6$  to  $1 \times 10^{10}$  pfu/ml (preferably  $1 \times 10^9$  to  $1 \times 10^{10}$  pfu/ml) in a volume of 1 to 500 ml, over a time period of 1 minute to 6 hours. If desired, multiple doses of the virus can be administered to a patient intravenously for several days in order to increase the level of expression as desired.

10 The optimal amount of virus or number of infected cells to be administered to a mammal and the frequency of administration are dependent upon factors such as the sensitivity of methods for detecting expression of the exogenous gene, the strength of the promoter used, the severity of the disorder to be treated, and the target cell(s) of the virus. Generally, the virus is 15 administered at a multiplicity of infection of about 0.1 to 1,000; preferably, the multiplicity of infection is about 5 to 100; more preferably, the multiplicity of infection is about 10 to 50.

V. Examples of Use of a Non-mammalian Virus to Express an Exogenous Gene *In Vivo*

20 The following examples demonstrate that a non-mammalian DNA virus can be used to express an exogenous gene in a cell *in vivo*. These examples also demonstrate that *in vivo* gene expression can be achieved by administering the virus by intravenous injection, intranasal administration, or direct injection of the virus into the targeted tissue. The first example demonstrates expression 25 of an exogenous gene in brain cells *in vivo*. The second example provides evidence of expression of an exogenous gene in liver, following intravenous injection of the virus. In the third example, expression of the exogenous gene is detected in skin after topical application of the Z4 virus to injured skin. In the remaining examples, a virus carrying an exogenous gene was injected 30 directly into an organ. These examples demonstrate *in vivo* expression of an

exogenous gene in skin, liver, spleen, kidney, stomach, skeletal muscle, uterus, and pancreas.

Injection Into Portal Vein: For the first example, 0.5 ml of Z4 virus ( $\approx 1.4 \times 10^9$  pfu/ml) was injected (at a rate of  $\approx 1$  ml/min) into the portal vein 5 of a single rat. At approximately 72 hours after infection, *lacZ* expression was detectable in at least one liver cell of the cryosections that were examined by conventional histochemical methods. The efficiency of expression may be increased by any one, or a combination of, the following procedures: (1) pre-treating the animal with growth factors; (2) partial hepatectomy, (3) 10 administration of immunosuppressants to suppress any immune response to the virus; (4) use of a higher titer or dose of the virus; (5) infusion of the virus by surgical perfusion to the liver (e.g., in order to limit possible non-specific binding of the virus to red blood cells); and/or (6) sonication of the virus to minimize clumping of the virus.

Expression in Brain: For the second example, a 2  $\mu$ l sample of Z4 virus 15 (at a titer of  $4.8 \times 10^{10}$  pfu/ml) was injected, using stereotactic procedure, into the olfactory bulb in the brain of an anesthetized adult rat. The virus was injected slowly (over a 30 minute time period) to avoid compressing the brain tissue. At 1 day post-injection, the rat was euthanized, and the brain tissue was 20 processed for detection of expression of the exogenous *lacZ* gene by X-gal histochemistry. Injection of the Z4 virus into the brain resulted in *in vivo* expression of *lacZ*, as was evidenced by patches of cells that were strongly stained blue. More than  $10^4$  cells were stained blue upon injection of 25 approximately  $10^7$  pfu. These data thus indicate that an exogenous gene can be expressed in the brain of a mammal by injecting into the brain a non-mammalian DNA virus whose genome includes the exogenous gene.

Topical Application and Expression in Skin: This example demonstrates 30 that topical application of the Z4 virus to abraded skin of a mouse can result in expression of a heterologous gene in the skin. These experiments involved four differently-treated areas on the skin of a mouse. Two of the areas (an abraded and a non-abraded area) were treated with phosphate-buffered saline. The other two areas (an abraded and a non-abraded area) were treated with the Z4 virus

(50  $\mu$ l at  $4.8 \times 10^{10}$  pfu/ml). After treatment, each area of the skin was cut into sections using a cryostat.

Topical application of the Z4 virus (50  $\mu$ l at  $4.8 \times 10^{10}$  pfu/ml) to injured skin of a mouse resulted in expression of the exogenous gene in nearly 100% of the cells of the basal layer of the epidermis. Staining of deeper structures was not detected. In one cryostat section, various areas of the epidermis were stained in multiple sections. In a second cryostat section, occasional blue cells were present. In a third cryostat section, patches of staining were detected, and in a fourth cryostat section, the staining was nearly continuous and very dark.

10 Although the pattern of gene expression varied slightly between the four cryostat sections obtained from this area of skin, the example demonstrates that topical application of the Z4 virus to abraded skin consistently resulted in expression of the heterologous gene in skin.

Injection Into a Tissue or Organ: In the following examples, expression of an exogenous gene was detected *in vivo* after a non-mammalian DNA virus carrying the gene was injected directly into four distinct organs. For these examples, the Z4 virus was prepared from 1 L of Z4-infected (moi of 0.5) Sf9 cells grown in spinner culture in serum-free medium. The cells and debris were removed by centrifuging the cell culture at 2000 rpm for 10 minutes. The virus was pelleted by centrifugation through a sucrose cushion in an SW28 rotor at 24,000 rpm for 75 minutes. For preparation of this virus stock, 33 ml of cleared virus was layered over a 3 ml sucrose cushion (27% sucrose (w/v) in 10 mM Tris-HCl (pH 7.5), 1 mM EDTA (TE)). The virus was resuspended by overnight incubation at 4°C in 0.3 ml TE per tube. The virus was purified by banding in a 20-60% sucrose (w/v in TE) gradient in SW41 tubes that were centrifuged at 38,000 rpm for 75 minutes. The virus bands were collected with a syringe and pelleted in SW50.1 rotor centrifuged at 30,000 rpm for 60 minutes. The virus pellet was resuspended in a total of 0.7 ml PBS by overnight incubation at 4°C. The titer of the concentrated Z4 stock, as determined in a conventional plaque assay, was  $4.8 \times 10^{10}$  pfu/ml.

To assay for gene expression *in vivo*, the Z4 virus was administered Balb/c female mice by direct injection of a 50  $\mu$ l aliquot of the concentrated

virus ( $2.4 \times 10^9$  pfu total) into either the liver, spleen, kidney, muscle, uterus, pancreas, or skin of a mouse. Surgery was required for administration to liver, spleen and kidney. To spread the virus throughout an organ, the  $50 \mu\text{l}$  virus sample was injected into two or three sites in an organ. A  $50 \mu\text{l}$  sample of

5 PBS was used as a negative control. For assaying gene expression in the liver, only one lobe of the liver was injected, and a separate mouse received the PBS injection as a negative control. For assaying gene expression in the spleen, an uninjected mouse served as a negative control. For assaying gene expression in kidney, muscle, and skin, contralateral controls were performed (the Z4 virus

10 was injected into the right side of the organ, and PBS was injected into the left of the organ). For assaying expression in muscle, the virus was injected into the tibialis anterior hind leg muscle after shaving the mouse. For assaying expression in skin, the abdomen of the mouse was shaved, and  $50 \mu\text{l}$  of Z4 virus were injected into a marked section of the abdomen. At 24 hours post-

15 injection, the mice were sacrificed and dissected. The Z4- and PBS-injected organs were frozen in liquid nitrogen, and  $7 \mu\text{m}$  thin sections were prepared using a cryostat (Reichert-Jung Cryocut 1800).  $\beta$ -galactosidase activity was measured by fixing the thin sections and staining with X-gal, as described above. Each of the organs that received the Z4 virus expressed the exogenous

20 *lacZ* gene *in vivo*. In each case, the PBS negative control did not promote expression of the exogenous gene.

Injection and Expression in Skin: In this example, *in vivo* expression of the exogenous *lacZ* gene of Z4 was observed in mouse skin after injection of  $2.4 \times 10^9$  pfu into the skin. A high level of expression (over 25% of cells

25 within the area of injection) was achieved in the dermis after subcutaneous injection of the virus. Although the muscle layer was predominantly unstained, positive staining of some skeletal muscle fibers was observed. As a negative control, PBS was injected into the skin. Although some staining was observed in the sebaceous glands, it is most probably due to the presence of bacteria. A

30 low level of staining was also detected in the dermis. Similar results were obtained when the Z4 virus was applied topically to uninjured (non-abraded) skin, although no clear epidermal staining was detected. Nonetheless, these

data indicate that the Z4 virus can be used to express a heterologous gene in the skin of a mammal when the virus is injected subcutaneously into the mammal.

Expression in Liver: In this example, expression of the exogenous gene was detected in liver. Blue coloration, indicative of  $\beta$ -galactosidase expression, was detected in multiple areas of the injected lobe. Although the most intense coloration was at the point of injection, the internal areas of the liver sections exhibited the blue coloration that is indicative of gene expression. Expression of the exogenous gene appeared to be detected both in hepatocytes and Kupffer cells of the lobes that received the Z4 virus. In contrast, uninjected lobes from the same liver were negative. These results thus indicate that an exogenous gene can be expressed in a liver cell by injecting into the liver a non-mammalian DNA virus encoding the gene.

Expression in Spleen: In this example, thin sections of the spleen were assayed for gene expression following injection of the virus carrying the exogenous gene into the spleen. Spleen cells that had received the Z4 virus *in vivo* expressed the *lacZ* gene. The blue coloration was detected in cells located throughout the entire spleen. The intensity of blue coloration obtained with spleen cells was less than the intensity obtained with liver cells. Nonetheless, the blue coloration was indicative of significant expression of the exogenous gene. No blue coloration was detected in a spleen that did not receive the virus. These data thus indicate that an exogenous gene can be expressed in a spleen cell *in vivo* upon injection of a non-mammalian DNA virus whose genome carries the gene.

Expression in Kidney: In this example, *in vivo* expression of an exogenous gene was detected in a kidney that was injected with Z4 as described above. The Z4-injected kidney displayed clear blue coloring that is indicative of *lacZ* expression; in contrast, a PBS-injected control kidney displayed no blue coloration. The blue coloration was primarily around the edges of the sections of the kidney. Indirect immunofluorescence also indicated that the viral particles were concentrated in the edges of the sections, providing a correlation between gene expression and localization of the virus. These data thus indicate

that a non-mammalian DNA virus can be used to express an exogenous gene in a kidney cell *in vivo*.

Expression in Stomach: In this example, the Z4 virus (50  $\mu$ l) was injected into the center of the stomach of Balb/C mice. The animals were 5 sacrificed on the day following injection, and the stomachs were frozen in liquid nitrogen, and cryostat sectioned and stained as previously described. Cell transfection was observed in gastric mucosal and muscle cells. Positive staining was detected in glands, with most staining occurring at the bases of the glands. These observations indicate that a non-mammalian DNA virus can be used to 10 express a heterologous gene in the stomach of mice. In these experiments, blue staining was also detected in the lumen. The blue coloration in that particular region may result from bacteria in the gut, rather than expression from the virus.

Expression in Skeletal Muscle: In this example, *in vivo* expression of the 15 exogenous *lacZ* gene of Z4 was detected in muscle after direct injection of virus into the tibialis anterior. Blue coloration was found only in discrete loci in the muscle, and the coloration was not as intense or widespread as the coloration observed in liver, spleen, or skin. Nonetheless, the blue coloration was significant, indicating that a non-mammalian DNA virus can be used to 20 express an exogenous gene in muscle *in vivo*.

Expression in Uterus: In this example, expression of the *lacZ* reporter gene was detected in the uterus. A 50  $\mu$ l aliquot of the Z4 virus ( $2.4 \times 10^9$  pfu) was injected directly into the uterus of a mouse. The animal was sacrificed on the day following injection, and cryostat sections were prepared as 25 previously described. Staining of the sections with X-gal produced blue coloration in an area of the uterus with little tissue disruption. The positive cells were mostly endometrial stromal cells, rather than gland elements. These data indicate that a non-mammalian DNA virus can be used to express a heterologous gene in the uterus of a mammal.

30 Expression in Pancreas: This example demonstrates that a non-mammalian DNA virus can be used to express a heterologous gene in the pancreas of a mammal. A 50  $\mu$ l aliquot of the Z4 virus ( $2.4 \times 10^9$  pfu) was

injected directly into the pancreas of a mouse. On the day following injection, the mouse was sacrificed, and the pancreas was stained with X-gal according to conventional methods. Large areas of positive cells were detected, indicating that the Z4 virus successfully expressed the *lacZ* gene in the pancreas.

5        Summary: In sum, these examples demonstrate that a non-mammalian DNA virus (e.g., a baculovirus) can be used to express an exogenous gene in a mammalian cell *in vivo*. These examples employed several distinct animal model systems and methods of administering the virus. In each and every case, the non-mammalian DNA virus successfully expressed the exogenous gene *in* 10 *vivo*. These data thus provide support for the assertion that a non-mammalian DNA virus can be used to express an exogenous gene in other, non-exemplified cells *in vivo*. In addition, in at least some tissues, the level of expression *in* 15 *vivo* was, surprisingly, higher than the level that would have been predicted from the corresponding *in vitro* experiments (e.g., the brain versus cultured neurons). All of these examples provide evidence of the *in vivo* utility of the invention.

What is claimed is:

1. A method of expressing an exogenous gene in a mammalian cell, said method comprising:
  - a) introducing into the cell a non-mammalian DNA virus the genome of which comprises said exogenous gene under the control of a promoter that induces expression of the exogenous gene in the cell; and
  - b) maintaining the cell under conditions such that said exogenous gene is expressed.
2. The method of claim 1, wherein said virus is an insect virus.
- 10 3. The method of claim 2, wherein the insect virus is an *Aedes* Densovirus.
4. The method of claim 2, wherein the insect virus is a *Bombyx mori* Nuclear Polyhedrosis Virus.
- 15 5. The method of claim 1, wherein said cell is selected from the group consisting of liver cells, kidney cells, neuronal cells, fibroblasts, cells of the central nervous system, splenic cells, muscle cells, skin cells, endothelial cells, epithelial cells, and bone marrow stem cells.
6. The method of claim 1, wherein said cell is a primary cell.
- 20 7. The method of claim 6, further comprising introducing said primary cell into a mammal.
8. The method of claim 1, wherein said virus is introduced into said cell *in vitro*.
9. The method of claim 1, wherein said mammalian cell is a human cell.
- 25 10. The method of claim 1, wherein said virus is introduced into said cell by administering said virus to a mammal comprising said cell.
11. The method of claim 1, wherein said gene is transcribed into an antisense RNA.
12. A method of treating a disorder in a mammal, comprising:
  - 30 a) introducing into a cell a therapeutically effective amount of a non-mammalian DNA virus to produce an infected cell, wherein the genome of the

b) maintaining the infected cell under conditions such that said exogenous gene is expressed in said mammal.

13. The method of claim 12, wherein said non-mammalian DNA virus is an insect virus.

5 14. A method for treating a cancer in a mammal, said method comprising:

a) introducing into a cancerous cell of said mammal a non-mammalian DNA virus the genome of which comprises a cancer-therapeutic gene selected from the group consisting of tumor necrosis factor, p53, thymidine kinase, 10 diphtheria toxin chimeras, and cytosine deaminase; and

b) maintaining the cell in said mammal under conditions such that said cancer-therapeutic gene is expressed.

15. The method of claim 14, wherein said cancerous cell is selected from the group consisting of hepatocytes, pancreatic cells, lung cells, thyroid 15 cells, thymus cells, brain cells, neuronal cells, glial cells, skin cells, breast tissue cells, prostate tissue cells, spleen cells, muscle cells, kidney cells, and bladder cells.

16. A method for treating a neurological disorder in a mammal, said method comprising:

20 a) introducing into a cell a therapeutically effective amount of a non-mammalian DNA virus to produce an infected cell, wherein the genome of the virus comprises an exogenous gene encoding a therapeutic protein selected from the group consisting of nerve growth factor, hypoxanthine guanine phosphoribosyl transferase, tyrosine hydroxylase, dopa-decarboxylase, brain-derived neurotrophic factor, and basic fibroblast growth factor; and 25

b) maintaining the infected cell under conditions such that said exogenous gene is expressed in said mammal.

17. The method of claim 16, wherein said cell is selected from the group consisting of fibroblasts, myoblasts, neuronal cells, and kidney cells.

18. A nucleic acid comprising:

a genome of a non-mammalian DNA virus;  
an exogenous mammalian gene; and  
an exogenous mammalian-active promoter operably linked to said

5 exogenous gene.

19. The nucleic acid of claim 18, wherein said virus is an insect virus.

20. A nucleic acid comprising:

a genome of a non-mammalian DNA virus;  
an exogenous antisense RNA gene, the RNA encoded by said

10 gene being complementary to a nucleic acid of a gene that is expressed in a cell  
at an undesirably high level; and

an exogenous mammalian-active promoter operably linked to said  
exogenous antisense RNA gene.

21. The nucleic acid of claim 20, wherein said virus is an insect virus.

15 22. A cell that contains a nucleic acid, wherein said nucleic acid  
comprises:

a genome of a non-mammalian DNA virus;  
an exogenous mammalian gene; and  
an exogenous mammalian-active promoter operably linked to said

20 exogenous gene.

23. The cell of claim 22, wherein said virus is an insect virus.

24. The cell of claim 22, wherein said cell is a primary cell.

25. A nucleic acid comprising:

a genome of a non-mammalian DNA virus;

25 an exogenous cancer therapeutic gene selected from the group consisting  
of tumor necrosis factor genes, thymidine kinase genes, chimeric diphtheria  
toxin genes, and cytosine diaminase genes; and

an exogenous mammalian-active promoter operably linked to said  
exogenous cancer therapeutic gene.

30 26. The nucleic acid of claim 25, wherein said virus is an insect virus.

27. A nucleic acid comprising:

a genome of a non-mammalian DNA virus;

an exogenous gene selected from the group consisting of RNA decoy genes and ribozyme genes; and

an exogenous mammalian-active promoter operably linked to said exogenous gene.

5 28. A pharmaceutical composition comprising:

(A) a pharmaceutically acceptable excipient and

(B) a nucleic acid, said nucleic acid comprising:

a genome of a non-mammalian DNA virus;

an exogenous mammalian gene; and

10 an exogenous mammalian-active promoter operably linked to said gene.

29. The pharmaceutical composition of claim 28, wherein said virus is an insect virus.

30. A non-mammalian DNA virus comprising the nucleic acid of claim  
15 18.

31. The non-mammalian DNA virus of claim 30, wherein the virus is an insect virus.

FIG. 1

## AcMNPV Transfer Plasmid Z4





FIG. 2

## AcMNPV Transfer Plasmid Z5



## AcMNPV Transfer Plasmid Z-EBV #1

FIG. 3




FIG. 4 A - B

### Scheme for auto-excising episome




FIG 4A

FIG. 4B

FIG. 5

## AcMNPV Transfer Plasmid pBV-AVneo




FIG. 6

## ACMNPV Transfer Plasmid CMV-BV




FIG. 7

## AcMNPV Transfer Plasmid CMVZ-BV





FIG. 8

## ACMNPV Transfer Plasmid Act-BV



# AcMNPV Transfer Plasmid AZ-BV

FIG. 9




FIG. 10





FIG. 11

## AcMNPV Transfer Plasmid NSE4-BV



# AcMNPV Transfer Plasmid TH/SV40/BP9

FIG. 12




FIG. 13




FIG. 14A - 14D

14 A

14 B

14 C

14 D



FIG. 15



FIG. 16




FIG. 17






Figure 18


A



B



C



D

